1206 articles by Jonathan Gardner

• Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

  Oct. 8, 2026

• Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

  Oct. 6, 2026

• Shionogi pays $2B to acquire a rare disease startup

  Oct. 5, 2026

• This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking

  Oct. 2, 2026

• 3 takeaways from a European obesity scientific meeting

  Oct. 1, 2026

• Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

  Sept. 30, 2026

• Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

  Sept. 29, 2026

• Kodiak skyrockets on positive study data for 2 eye drugs

  Sept. 28, 2026

• FDA nominee Overton parries vaccine questions at Senate hearing

  Sept. 24, 2026

• Roche, Ionis RNA drug scores in kidney disease study

  Sept. 23, 2026

• Viking shares surge on updated obesity drug data

  Sept. 22, 2026

• Novo talks up drug launches in effort to win back investors

  Sept. 21, 2026

• Xenon shares fall following depression trial pause

  Sept. 18, 2026

• Novo partners with Orbis, deepening investment in oral peptide drugs

  Sept. 17, 2026

• WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight

  Sept. 15, 2026

• Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

  Sept. 14, 2026

• Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing

  Sept. 14, 2026

• Tyra disappoints investors with bladder cancer data

  Sept. 9, 2026

• Trailing rivals, AbbVie scores win with dual-acting myeloma drug

  Sept. 4, 2026

• Akeso, Summit cancer drug confirms lung cancer survival benefit

  Sept. 3, 2026

• Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

  Sept. 2, 2026

• Mid-cap biotechs join Trump’s latest round of drug pricing deals

  Sept. 1, 2026

• Lilly adds to immune drug pipeline with $2.9B Merida buyout

  Aug. 31, 2026

• AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

  Aug. 28, 2026

• New Jazz cancer drug approval could drive blockbuster sales

  Aug. 25, 2026

• Roche commits to lean-mass preservation with Hanmi obesity deal

  Aug. 24, 2026

• Regeneron to challenge Ipsen as FDA clears bone disease drug

  Aug. 20, 2026

• Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma

  Aug. 19, 2026

• BioMarin acquires experimental drug for rare bone disorder in $275M deal

  Aug. 18, 2026

• AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer

  Aug. 17, 2026

• Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

  Aug. 14, 2026

• New Taiho, Cullinan data heats up lung cancer drug battle

  Aug. 13, 2026

• Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

  Aug. 11, 2026

• Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

  Aug. 10, 2026

• Replimune rebounds to win FDA approval of melanoma drug

  Aug. 6, 2026

• Attovia adds to biotech IPO momentum with $289M offering

  Aug. 5, 2026

• Pfizer expands multibillion-dollar cost-cutting plan

  Aug. 4, 2026

• Supernus, Indivior merge to beef up brain drug portfolio

  Aug. 3, 2026

• Novo setback casts doubt on a new way to treat heart disease

  July 31, 2026

• Replimune melanoma drug wins support of FDA panel

  July 30, 2026

• Crystalys nets $130M more to push gout drug through late-stage tests

  July 22, 2026

• Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs

  July 21, 2026

• GSK shelves cough drug acquired in $2B deal

  July 17, 2026

• Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

  July 14, 2026

• Q32 bounces back to claim study success for alopecia drug

  July 13, 2026

• Roche scraps two Ionis-partnered Huntington’s drugs

  July 9, 2026

• AstraZeneca, GSK intensify China ties with Sino Biopharm deals

  July 8, 2026

• Kailera says obesity pill succeeds in late-stage trial in China

  July 7, 2026

• Abivax shares surge as worries subside over immune drug’s cancer risk

  July 1, 2026

• Top FDA gene and cell therapy regulator to step down

  June 30, 2026

• Theravance, after clinical setbacks, agrees to $929M buyout

  June 29, 2026

• On second try, Acadia drug gets nod from European regulators

  June 26, 2026

• HHS, responding to China’s rise, moves to fast-track early drug research

  June 23, 2026

• Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

  June 22, 2026

• cAMPfield lands $180M to build gut disease drug

  June 18, 2026

• Edgewise heart drug passes key trial test

  June 16, 2026

• Medicare drug price rule may target under-the-skin Keytruda and Opdivo

  June 15, 2026

• Summit pulls $500M share sale a day after announcing it

  June 11, 2026

• Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

  June 11, 2026

• GSK boosts cancer pipeline with $11B Nuvalent buyout

  June 9, 2026

• Tango data add to growing momentum for pancreatic cancer drugs

  June 8, 2026

• Generic drugmakers gain key victory in ‘skinny label’ patent case

  June 5, 2026

• Legend surges on early data for ‘in vivo’ lymphoma cell therapy

  June 3, 2026

• ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

  June 2, 2026

• ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

  May 31, 2026

• Akeso, Summit drug extends survival in closely watched lung cancer trial

  May 31, 2026

• Bristol Myers unveils data for one of its next-gen blood cancer drugs

  May 29, 2026

• GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

  May 28, 2026

• Kailera’s three-pronged obesity shot shows promise in early trial

  May 27, 2026

• Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

  May 26, 2026

• Lilly’s triple-acting obesity drug hits goal in Phase 3 trial

  May 21, 2026

• After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets

  May 20, 2026

• Merck ADC, licensed from China, hits mark in first big global trial

  May 18, 2026

• FDA hold puts Aardvark Prader-Willi drug in limbo

  May 15, 2026

• FDA’s leadership void leaves biotech with renewed ‘uncertainty’

  May 13, 2026

• Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

  May 1, 2026

• Merck still sees ‘compelling’ outlook for Terns leukemia drug

  April 30, 2026

• Boehringer dual-acting obesity shot hits mark in Phase 3 trial

  April 28, 2026

• Veradermics soars on positive data for baldness treatment

  April 27, 2026

• Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

  April 23, 2026

• Revolution drug shows promise in early pancreatic cancer

  April 22, 2026

• Nektar surges again as alopecia drug shows new promise in extension study

  April 20, 2026

• Lilly’s new obesity pill passes heart safety test in diabetes

  April 16, 2026

• FDA asks Lilly to evaluate obesity pill’s liver risk

  April 15, 2026

• J&J leans on Tremfya, cancer drugs to overcome Stelara losses

  April 14, 2026

• Revolution pancreatic cancer drug nearly doubles survival in key trial

  April 13, 2026

• With 3 quick buyouts, Gilead leans into its latest transformation

  April 8, 2026

• Terns rebuffed a higher bid before selling to Merck

  April 7, 2026

• Trump revives pharma tariffs with 100% charges, but leaves loopholes

  April 3, 2026

• FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

  April 1, 2026

• FDA, after turbulent year, leaves drugmakers guessing on its direction

  April 1, 2026

• Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout

  March 31, 2026

• Lilly’s AI commitment expands through deal with Insilico

  March 30, 2026

• AstraZeneca lung drug gets ‘surprise’ win in COPD trials

  March 27, 2026

• Merck’s deal for Terns sparks debate over a possible biotech bidding war

  March 26, 2026

• Karyopharm myeloma drug yields mixed data in myelofibrosis trial

  March 24, 2026

• Apogee strengthens case for longer-lasting eczema drug

  March 23, 2026

• Lilly’s three-pronged obesity drug hits goal in large diabetes trial

  March 19, 2026

• Bicycle to lay off 30% of staff, pivot away from Padcev challenger

  March 17, 2026

• Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial

  March 16, 2026

• Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders

  March 12, 2026

• Lilly unveils $3 billion production expansion in China

  March 11, 2026

• Roche’s prized breast cancer pill fails closely watched study

  March 9, 2026

• Vinay Prasad, controversial FDA leader, to again depart agency

  March 6, 2026

• FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo

  March 6, 2026

• Lilly targets employers in new bid to broaden access to obesity drugs

  March 5, 2026

• Blackstone puts $400M into Teva, Sanofi gut disease drug

  March 4, 2026

• Pierre Fabre seeks to revive US approval chances for spurned cell therapy

  March 3, 2026

• Roche pill succeeds in another MS study, but approval questions linger

  March 2, 2026

• Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

  Feb. 26, 2026

• Alkermes’ Richard Pops to step down after three-decade run as CEO

  Feb. 25, 2026

• Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study

  Feb. 23, 2026

• Roche gets FDA decision date on closely watched breast cancer drug

  Feb. 20, 2026

• Ultragenyx cuts jobs as it seeks path to profit in 2027

  Feb. 13, 2026

• Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study

  Feb. 10, 2026

• Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals

  Feb. 9, 2026

• White House’s online service for drug sales debuts with limited impact on prices

  Feb. 6, 2026

• Bayer details anticipated stroke prevention data for new blood-thinner

  Feb. 5, 2026

• Novo shares tumble by double digits on grim sales outlook

  Feb. 4, 2026

• Pfizer dips on new data for obesity drug acquired in $10B deal

  Feb. 3, 2026

• Novo combination obesity shot meets goal in diabetes trial

  Feb. 2, 2026

• Amgen gives up on its once-prized eczema drug

  Jan. 30, 2026

• Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts

  Jan. 28, 2026

• Roche, trailing in obesity, showcases new data for GLP-1 shot

  Jan. 27, 2026

• Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time

  Jan. 26, 2026

• Sanofi to seek approval of touted eczema drug despite mixed results

  Jan. 23, 2026

• FDA lays out new path to speed development of multiple myeloma drugs

  Jan. 22, 2026

• Corvus shares nearly triple on positive data for eczema pill

  Jan. 21, 2026

• Tecvayli tops standard drugs in early multiple myeloma, J&J says

  Jan. 15, 2026

• Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill

  Jan. 14, 2026

• Alveus launches with $160M to advance MariTide-like obesity drug

  Jan. 8, 2026

• Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs

  Jan. 7, 2026

• Alumis soars as TYK2 drug hits mark in psoriasis trials

  Jan. 6, 2026

• Zenas shares crash after top drug misses expectations in immune disease study

  Jan. 5, 2026

• Novo Nordisk’s weight loss pill approved by FDA

  Dec. 23, 2025

• Galapagos TYK2 drug hits goal in one trial, misses in another

  Dec. 19, 2025

• Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

  Dec. 18, 2025

• Argenx falters in effort to expand immune drug’s use

  Dec. 15, 2025

• Arcus cancels work on Gilead-partnered cancer combo after trial setback

  Dec. 12, 2025

• Novartis notches another win for drug acquired in MorphoSys deal

  Dec. 9, 2025

• J&J’s ‘remarkable’ Tecvayli data support earlier use in multiple myeloma

  Dec. 9, 2025

• Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment

  Dec. 8, 2025

• At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma

  Dec. 7, 2025

• Vertex CRISPR therapy hits early goal in children with blood disorders

  Dec. 6, 2025

• 12 former FDA chiefs blast Prasad’s move to toughen vaccine standards

  Dec. 4, 2025

• Pharvaris’ pill succeeds in late-stage trial for rare swelling disorder

  Dec. 3, 2025

• FDA details plan to scale back animal tests for some antibody drugs

  Dec. 2, 2025

• UK agrees to boost drug prices to dodge US pharma tariffs

  Dec. 1, 2025

• CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

  Nov. 26, 2025

• Novartis wins approval to use SMA gene therapy in older patients

  Nov. 25, 2025

• Bayer’s experimental blood-thinner notches trial win in stroke prevention

  Nov. 24, 2025

• Eli Lilly becomes first drugmaker to hit $1 trillion in market value

  Nov. 21, 2025

• GSK, Anaptysbio sue each other over Jemperli revenue

  Nov. 21, 2025

• Agios shares fall on mixed sickle cell results for blood disease drug

  Nov. 19, 2025

• Roche pill notches win in early breast cancer

  Nov. 18, 2025

• J&J adds to pharma’s M&A spree with $3B buyout of startup Halda

  Nov. 17, 2025

• Bristol Myers, J&J’s new blood thinner fails first big test

  Nov. 14, 2025

• Day One snaps up ADC maker Mersana in backloaded buyout deal

  Nov. 13, 2025

• Merck showcases data suggesting PCSK9 pill might rival cholesterol-lowering shots

  Nov. 10, 2025

• Novo, Lilly cut deal with Trump to lower prices of obesity drugs

  Nov. 6, 2025

• FTC signals scrutiny of Novo’s bid for Metsera

  Nov. 5, 2025

• Metsera again chooses Novo as bidding war with Pfizer intensifies

  Nov. 4, 2025

• Caribou results suggest renewed promise for ‘off-the-shelf’ cancer cell therapy

  Nov. 3, 2025

• Novo tops Pfizer with $6.5B bid for Metsera

  Oct. 30, 2025

• FDA, aiming to lower drug costs, moves to speed approval of biosimilars

  Oct. 29, 2025

• Lilly aligns with Walmart in bid to broaden access to discounted Zepbound

  Oct. 29, 2025

• Merck kidney cancer drug succeeds in two large trials

  Oct. 28, 2025

• Intellia pauses two CRISPR drug studies after safety scare

  Oct. 27, 2025

• Novo’s main shareholder pushes out more than half of company’s board

  Oct. 21, 2025

• Summit’s dual-acting drug scores lung cancer win

  Oct. 20, 2025

• Roche pill delays tumor progression in closely watched breast cancer study

  Oct. 18, 2025

• J&J claims success in study testing earlier Tecvayli use in multiple myeloma

  Oct. 16, 2025

• Kailera nets $600M more to advance Zepbound-like obesity drug

  Oct. 14, 2025

• Bristol’s $1.5B Orbital buyout extends ‘in vivo’ cell therapy deal streak

  Oct. 10, 2025

• Novo joins MASH dealmaking surge with $4.7B Akero buyout

  Oct. 9, 2025

• Peter Marks, former top FDA vaccine official, joins Eli Lilly

  Oct. 7, 2025

• Amgen claims ‘landmark’ study result that could widen heart drug’s use

  Oct. 2, 2025

• Trump, Pfizer drug pricing deal short on details, possible impact

  Sept. 30, 2025

• Metsera strengthens case for Pfizer buyout with latest study data

  Sept. 30, 2025

• Emma Walmsley, big pharma’s first female CEO, to depart GSK

  Sept. 29, 2025

• Key exemptions could limit impact of Trump’s pharmaceutical tariffs

  Sept. 26, 2025

• Lilly stops trial of muscle-sparing obesity drug

  Sept. 25, 2025

• UniQure to seek approval of Huntington’s gene therapy after trial win

  Sept. 24, 2025

• Bristol Myers says next-gen blood cancer drug hits goal in key study

  Sept. 23, 2025

• Pfizer buys back into obesity drug chase with $4.9B Metsera deal

  Sept. 22, 2025

• CDC panel, recast by RFK Jr., softens COVID vaccine recommendations

  Sept. 19, 2025

• CDC panel recommends splitting measles, varicella shots

  Sept. 18, 2025

• Roivant pill succeeds in rare inflammatory disease trial

  Sept. 17, 2025

• ATyr shares plunge on trial miss in inflammatory lung disease

  Sept. 15, 2025

• FDA clears J&J’s drug-device combo for bladder cancer

  Sept. 10, 2025

• BioNTech says dual-acting lung cancer drug helped shrink tumors

  Sept. 8, 2025

• New Summit data clouds approval pathway in lung cancer

  Sept. 8, 2025

• At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves

  Sept. 4, 2025

• Ionis looks to expand use of lipid-lowering drug after trial hits goal

  Sept. 2, 2025

• Lilly to submit obesity pill after hitting goal in third late-stage trial

  Aug. 26, 2025

• Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales

  Aug. 25, 2025

• Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

  Aug. 21, 2025

• Viking shares sink as obesity pill misses expectations in key study

  Aug. 19, 2025

• Stealth resubmits rare disease drug to FDA

  Aug. 18, 2025

• Lilly says it will raise drug prices in Europe, responding to Trump threats

  Aug. 14, 2025

• Insmed gains US approval of lung disease drug forecast to be blockbuster

  Aug. 12, 2025

• Pfizer looks to expand ADC use after positive bladder cancer data

  Aug. 12, 2025

• IO Biotech sees path forward for skin cancer vaccine despite study setback

  Aug. 11, 2025

• BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal

  Aug. 8, 2025

• Lilly shares fall as obesity pill misses expectations in key trial

  Aug. 7, 2025

• Novo pushes back against obesity drug compounders as competition intensifies

  Aug. 6, 2025

• Trump redoubles threats in attempt to strongarm drugmakers on prices

  July 31, 2025

• Merck plans spending shift to boost business beyond Keytruda

  July 29, 2025

• Adaptimmune, seeking to stay afloat, sells off cell therapies

  July 28, 2025

• With Verona deal, Merck wagers on strength of lung drug’s patents

  July 11, 2025

• Lilly gets FDA OK of modified dosing for Alzheimer’s drug

  July 9, 2025

• After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder

  July 7, 2025

• Moderna flu shot outperforms marketed vaccines in large late-stage trial

  June 30, 2025

• RFK Jr.-appointed panel recommends flu shots be free of contested preservative

  June 26, 2025

• New Amgen obesity drug data disappoint Wall Street

  June 24, 2025

• Novo abruptly ends obesity drug deal with Hims

  June 23, 2025

• FDA to speed reviews for drugs supporting ‘national interests’

  June 18, 2025

• Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug

  June 16, 2025

• BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

  June 13, 2025

• Novo, searching for a spark, plans late-stage trials for amylin drug

  June 13, 2025

• Metsera shares climb on early data for amylin-targeting obesity shot

  June 9, 2025

• Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO

  June 4, 2025

• J&J data support earlier use of combo pill in prostate cancer

  June 3, 2025

• Bispecific competition, debating oral SERDs and a bold GLP-1 prediction

  June 2, 2025

• A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising

  June 1, 2025

• At ASCO, Enhertu cements growing role in stomach cancer care

  May 31, 2025

• Muscle-sparing obesity drug safe for Phase 3 trial, Veru says

  May 28, 2025

• Zepzelca, Tecentriq combo extends survival in hard-to-treat lung cancer

  May 22, 2025

• FDA panel backs Darzalex for early stage multiple myeloma

  May 21, 2025

• 5 questions on Trump’s plan to lower US drug prices

  May 13, 2025

• Trump revives ‘most favored nation’ plan in effort to cut US drug prices

  May 12, 2025

• Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.

  May 8, 2025

• Vinay Prasad, a physician and FDA critic, to lead agency center overseeing vaccines

  May 6, 2025

• Trump orders FDA to help speed building of new drug factories

  May 6, 2025

• Amgen’s Stelara biosimilar gets off to fast start

  May 2, 2025

• Pharma downplays tariff threat, even as risks remain unclear

  May 1, 2025

• Novo partners with telehealth companies in move to expand Wegovy market

  April 29, 2025

• Merck takes $200M tariff hit, trimming its gross profits

  April 24, 2025

• Roche, answering tariff threat, pledges $50B to US drug production

  April 22, 2025

• Novo says it’s submitted obesity pill for FDA approval

  April 21, 2025

• Lilly’s obesity pill scores in large diabetes trial

  April 17, 2025

• Safety worries spur Pfizer to drop another obesity pill

  April 14, 2025

• Amid tariff turmoil, Novartis commits to spending $23B on US manufacturing

  April 10, 2025

• Tempest seeks strategic alternatives as cash runs out for Phase 3 trial

  April 10, 2025

• Obesity drug data helps Rhythm defy market slide

  April 7, 2025

• Makary confirmed by Senate as FDA commissioner

  March 26, 2025

• Merck bets $200M on a new type of heart pill

  March 25, 2025

• Novo adds to obesity drug pipeline via $200M deal with China-based biotech

  March 24, 2025

• J&J boosts US manufacturing as big pharma reshores

  March 21, 2025

• Roche broadens obesity drug plans with $1.65B Zealand deal

  March 12, 2025

• Viking inks CordenPharma deal to boost obesity drug supply

  March 11, 2025

• Novo’s Wegovy successor disappoints in second large trial

  March 10, 2025

• Following FDA cuts, Trump nominee Makary vows ‘independent’ staff review

  March 6, 2025

• Jazz expands in oncology with $935M deal for Chimerix

  March 5, 2025

• AbbVie gets into obesity with $350M deal for once-weekly shot

  March 3, 2025

• Leqembi, after delay, gets back on track toward EU approval

  Feb. 28, 2025

• Drug compounders sue FDA over declaration ending Wegovy shortage

  Feb. 25, 2025

• Summit partners with Pfizer to study bispecific, ADC combinations

  Feb. 24, 2025

• In FDA job cuts, experts see threat of far-reaching impact

  Feb. 20, 2025

• New study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings

  Feb. 12, 2025

• Novo outlines new late-stage study of obesity drug CagriSema

  Feb. 5, 2025

• Merck shares tumble as company pauses Gardasil shipments to China

  Feb. 4, 2025

• RFK Jr. clears key hurdle on path to become HHS secretary

  Feb. 4, 2025

• Pfizer drug acquired in $11B buyout confirms benefit in colon cancer

  Feb. 3, 2025

• Trump administration affirms drug price talks, but will seek input to ‘improve’ program

  Jan. 29, 2025

• Versant invests again in obesity, this time backing Helicore Biopharma

  Jan. 28, 2025

• Muscle-building drug improves body composition in obesity trial, Veru says

  Jan. 27, 2025

• Novo shares climb on early data for dual-acting obesity drug

  Jan. 24, 2025

• AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer

  Jan. 21, 2025

• Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.

  Jan. 17, 2025

• JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

  Jan. 16, 2025

• JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

  Jan. 14, 2025

• Lilly blames slower-than-expected growth for 2024 sales miss

  Jan. 14, 2025

• 5 questions facing pharma in 2025

  Jan. 9, 2025

• Metsera reveals data supporting long-acting obesity shot

  Jan. 7, 2025

• Novo’s next-gen obesity drug misses expectations in closely watched trial

  Dec. 20, 2024

• Regeneron says study data support big bet on new blood thinners

  Dec. 19, 2024

• Merck moves into obesity with deal for Hansoh’s GLP-1 pill

  Dec. 18, 2024

• Merck calls quits on two immunotherapies for cancer

  Dec. 16, 2024

• With new data, Lilly sets pace for next wave of breast cancer drugs

  Dec. 11, 2024

• ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug

  Dec. 9, 2024

• Lilly adds to obesity drug production push with $3B investment

  Dec. 6, 2024

• Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives

  Dec. 4, 2024

• Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial

  Dec. 4, 2024

• Diabetes advocacy group discourages use of compounded GLP-1 drugs

  Dec. 2, 2024

• Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark

  Nov. 26, 2024

• New data could help Merck expand use of cardiovascular drug

  Nov. 25, 2024

• Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

  Nov. 22, 2024

• Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says

  Nov. 19, 2024

• ‘Find any advantage’: 3 biotech leaders on driving R&D success

  Nov. 15, 2024

• BioNTech to buy Biotheus, gaining control of cancer bispecific

  Nov. 13, 2024

• FDA approves new CAR-T competitor to Gilead’s Tecartus

  Nov. 11, 2024

• Novo sees Wegovy sales rise as supply constraints ease

  Nov. 6, 2024

• Cancer cell therapy from Arcellx, Gilead shows promise in early data

  Nov. 5, 2024

• Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs

  Nov. 4, 2024

• Roche weighs whether speedy approval path is open for latest Alzheimer’s drug

  Oct. 31, 2024

• Oral version of Novo diabetes drug protects heart health in large study

  Oct. 21, 2024

• Gilead withdraws Trodelvy in bladder cancer

  Oct. 18, 2024

• Novocure wins FDA approval for electric field device in lung cancer

  Oct. 16, 2024

• Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss

  Oct. 15, 2024

• FDA, facing pressure, to review position on Zepbound, Mounjaro shortage

  Oct. 14, 2024

• Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.

  Oct. 10, 2024

• Roche turns to a startup in search for new breast cancer drugs

  Sept. 30, 2024

• Novo CEO pressed by Senate to cut prices of obesity, diabetes drugs

  Sept. 24, 2024

• AstraZeneca, Daiichi’s Enhertu successor faces more questions after latest stumble

  Sept. 23, 2024

• ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial

  Sept. 17, 2024

• ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy’s survival impact

  Sept. 16, 2024

• Ten-year survival data show long-term benefit of immunotherapy in melanoma

  Sept. 15, 2024

• Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test

  Sept. 12, 2024

• House backs bill restricting China role in US biotech

  Sept. 10, 2024

• Early study data puts Terns among obesity drug contenders

  Sept. 9, 2024

• Lilly builds case for weekly insulin shot

  Sept. 5, 2024

• A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

  Sept. 4, 2024

• New research could ease concerns over suicide risk of obesity drugs

  Sept. 3, 2024

• Keytruda fails lung and skin cancer trials, limiting further expansion

  Aug. 29, 2024

• Regeneron gains European approval for bispecific lymphoma drug

  Aug. 26, 2024

• FDA lifts partial hold on study of BioNTech-partnered ADC

  Aug. 19, 2024

• Medicare drug price cuts could have limited early impact, but grow with time

  Aug. 16, 2024

• Startup Halda raises $126M to advance new type of targeted cancer therapy

  Aug. 12, 2024

• Pfizer’s Bourla confident in company’s obesity drug position, despite delays

  July 30, 2024

• Ventyx’s TYK2 drug suffers second setback

  July 29, 2024

• Boehringer cuts price of Humira biosimilar in bid to build use

  July 18, 2024

• Obesity pill from Roche shows promising weight loss in small study

  July 17, 2024

• Cardurion raises another $260M to fuel heart drug pipeline

  July 16, 2024

• Lilly drug for Alzheimer’s approved by FDA

  July 2, 2024

• Eisai and Bristol Myers cancel cancer ADC deal

  July 1, 2024

• Novo nixes trial of blood pressure drug it bought in $1.3B deal

  June 26, 2024

• Novo to spend $4B on US plant, adding to obesity drug production push

  June 25, 2024

• Obesity drug from Zealand shows potential in early trial

  June 20, 2024

• FDA lifts hold on PTC Huntington’s disease trial

  June 20, 2024

• Takeda drug for rare types of epilepsy misses goal in late-stage trial

  June 17, 2024

• AbbVie joins in latest gastrointestinal drug chase

  June 14, 2024

• Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say

  June 11, 2024

• Lilly Alzheimer’s drug gets unanimous backing of FDA panel

  June 10, 2024

• In review of Lilly Alzheimer’s drug, FDA staff focus on safety, patient selection

  June 6, 2024

• Viking says biopsy data confirm MASH drug’s benefit

  June 4, 2024

• AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer

  June 2, 2024

• GSK builds case for return of multiple myeloma drug Blenrep

  June 2, 2024

• AstraZeneca’s $80B sales plan leans on cancer drug expansion

  May 21, 2024

• AstraZeneca sets sights on $80B in revenue by 2030

  May 21, 2024

• FDA approves Amgen drug for tough-to-treat form of lung cancer

  May 17, 2024

• Roche keeps pace in obesity drug field with early study data

  May 16, 2024

• Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug

  May 13, 2024

• Drug patents protect pharma profits. Track when they’ll expire.

  May 8, 2024

• AstraZeneca ups stake in Cellectis in latest cell therapy bet

  May 6, 2024

• Amgen shares soar as executives outline obesity drug push

  May 3, 2024

• Novo sees Wegovy sales dip on lower price, tight supply

  May 2, 2024

• Lilly counts on manufacturing scale-up to unstick obesity drug supply

  April 30, 2024

• Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound

  April 30, 2024

• AbbVie tries to reassure investors on Humira biosimilar threat

  April 26, 2024

• AstraZeneca’s earnings surprise investors as cancer drugs fuel growth

  April 25, 2024

• Eisai hunts for next Alzheimer’s drug with new research pact

  April 22, 2024

• Alvotech deal could heighten biosimilar pressure on Humira

  April 19, 2024

• Lilly obesity drug shows benefit in sleep disorder study, pointing to new use

  April 17, 2024

• Roche reports survival data for new dual-acting lymphoma drug

  April 15, 2024

• European regulator concludes no suicide link to obesity drugs

  April 12, 2024

• Novartis pauses enrollment in some Kisqali trials to fix manufacturing

  April 10, 2024

• Trial shows Wegovy can ease heart failure symptoms

  April 8, 2024

• Bristol Myers says KRAS drug succeeds in key trial

  March 29, 2024

• FDA approves Akebia anemia pill, two years after rejection

  March 28, 2024

• FDA approves Merck lung disease drug acquired in $11B deal

  March 26, 2024

• Viking stays in obesity drug race with early data for weight loss pill

  March 26, 2024

• FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

  March 25, 2024

• Roche autoimmune disease drug disappoints in closely watched trial

  March 21, 2024

• FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma

  March 15, 2024

• BIO changes stance, backs bill to limit China’s role in US biotech

  March 14, 2024

• FDA to focus on ‘early deaths’ in meeting on broader CAR-T use in myeloma

  March 13, 2024

• Roche, following setbacks, turns to its next Alzheimer’s drug

  March 11, 2024

• FDA delays decision on Lilly’s closely watched Alzheimer’s drug

  March 8, 2024

• Novo’s latest obesity pill spurs major weight loss in small trial

  March 7, 2024

• Alnylam, Roche blood pressure drug scores in second mid-stage trial

  March 5, 2024

• AstraZeneca’s drug pricing lawsuit dismissed by federal judge

  March 4, 2024

• Pfizer, looking for a jumpstart, leans into cancer drug research

  March 1, 2024

• Viking data suggest obesity drug could rival Zepbound, Wegovy

  Feb. 27, 2024

• Humira biosimilar from Alvotech, Teva wins FDA approval on third attempt

  Feb. 26, 2024

• Bavarian Nordic terminates cancer vaccine work

  Feb. 21, 2024

• Rick Gonzalez, longtime AbbVie CEO, to step down in July

  Feb. 20, 2024

• FDA to review expanded use of Sarepta Duchenne gene therapy

  Feb. 16, 2024

• BioAge raises $170M to back Phase 2-ready obesity drug

  Feb. 13, 2024

• CSL heart drug misses goal in large study

  Feb. 12, 2024

• Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts

  Feb. 8, 2024

• Lilly sales surge on obesity, diabetes drug demand

  Feb. 6, 2024

• Novo Holdings to buy contract drugmaker Catalent for $16.5B

  Feb. 5, 2024

• Roche shuffles early stage pipeline as it joins obesity rush

  Feb. 1, 2024

• Novo resumes supplying starter doses of obesity drug Wegovy

  Jan. 31, 2024

• Gilead deepens investment in Arcus and TIGIT drugs

  Jan. 30, 2024

• Bristol Myers gets positive data in subcutaneous Opdivo trial

  Jan. 29, 2024

• EMA recommends earlier use of Bristol Myers cell therapy for multiple myeloma

  Jan. 26, 2024

• FDA orders new cancer warnings for CAR-T therapies

  Jan. 23, 2024

• Gilead ADC medicine misses goal in closely watched lung cancer study

  Jan. 22, 2024

• Sanders threatens to subpoena J&J, Merck CEOs over drug prices

  Jan. 19, 2024

• FDA says no ‘clear relationship’ between GLP-1 drugs and suicide risk

  Jan. 12, 2024

• 5 questions facing pharma in 2024

  Jan. 10, 2024

• Merck pays $680M for struggling cancer biotech Harpoon

  Jan. 8, 2024

• FDA authorizes Florida to import drugs from Canada

  Jan. 5, 2024

• Pfizer wins Canadian OK for hemophilia treatment, its first gene therapy

  Jan. 3, 2024

• FDA ends busy year with three drug rejections

  Jan. 2, 2024

• 10 clinical trials to watch in the first half of 2024

  Jan. 2, 2024

• J&J bets bigger on MeiraGTx’s eye gene therapy

  Dec. 21, 2023

• GSK adds to ADC dealmaking with second Chinese biotech pact

  Dec. 20, 2023

• FDA widens use of cancer drug Merck acquired for $1B

  Dec. 15, 2023

• New Moderna cancer vaccine data spurs share rally

  Dec. 14, 2023

• Pfizer to deepen cost cuts as latest sales forecasts miss expectations

  Dec. 13, 2023

• FTC, in unusual move, leads Sanofi to terminate a drug research deal

  Dec. 12, 2023

• Humira leads ICER’s latest list of ‘unsupported’ price hikes

  Dec. 11, 2023

• Merck suffers bad week as 3 Keytruda combination trials fail

  Dec. 8, 2023

• Biden administration goes after drug patents in bid to lower prices

  Dec. 7, 2023

• BIO names longtime Amicus head John Crowley as new CEO

  Dec. 5, 2023

• Lilly cancer drug cleared by FDA for expanded leukemia, lymphoma use

  Dec. 4, 2023

• AbbVie joins ADC dealmaking with $10B ImmunoGen buyout

  Nov. 30, 2023

• FDA names chief scientist Bumpus as Woodcock’s successor

  Nov. 29, 2023

• FDA investigating cancer risk linked to CAR-T cell therapy

  Nov. 28, 2023

• Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

  Nov. 28, 2023

• GSK cancer drug Blenrep gets surprise trial win

  Nov. 27, 2023

• Bayer ends large blood thinner trial for ‘inferior efficacy’

  Nov. 20, 2023

• Lilly plans new $2.5B manufacturing plant as obesity drug demand ramps up

  Nov. 17, 2023

• Top FDA official Woodcock to retire early next year

  Nov. 16, 2023

• FDA approves new Bristol Myers drug for lung cancer

  Nov. 16, 2023

• Gilead expands Arcellx cancer cell therapy deal

  Nov. 15, 2023

• Novartis licenses Legend cell therapy for lung cancer

  Nov. 13, 2023

• Detailed trial data confirm Wegovy heart benefit

  Nov. 11, 2023

• AstraZeneca stays in GLP-1 drug race with new deal

  Nov. 9, 2023

• Lilly rival to weight loss drug Wegovy approved by FDA

  Nov. 8, 2023

• FTC challenges patents held by nine big drugmakers, citing unfair competition

  Nov. 8, 2023

• Novo, Lilly buoyed by fast-growing GLP-1 drug sales

  Nov. 2, 2023

• A play-by-play of the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy

  Oct. 31, 2023

• Sanofi to divest consumer unit, joining pharma industry shift

  Oct. 27, 2023

• Novartis delays FDA filing for in-demand radiopharma drug

  Oct. 24, 2023

• Merck cancer drug deal caps pharma investment influx into ‘ADC’ field

  Oct. 20, 2023

• Roche eye drug sales grow as Regeneron plays catch-up

  Oct. 19, 2023

• Keytruda gains first approval for pre- and post-surgery use in lung cancer

  Oct. 17, 2023

• Novo adds to deal spree with blood pressure drug buy

  Oct. 16, 2023

• Pfizer wins FDA approval for its $7B colitis drug

  Oct. 13, 2023

• Novo Nordisk’s Ozempic shows kidney benefit in large study

  Oct. 11, 2023

• Merck data show survival benefit to early Keytruda treatment

  Oct. 10, 2023

• FDA denies expanded approval for Alnylam RNA drug

  Oct. 9, 2023

• Amgen completes $28B Horizon buyout that was challenged by FTC

  Oct. 6, 2023

• Lilly names new diabetes and obesity chief as Mounjaro sales take off

  Oct. 4, 2023

• Viatris sells off consumer, women’s health drugs in asset sales

  Oct. 2, 2023

• 5 FDA decisions to watch in the fourth quarter

  Oct. 2, 2023

• Roche bets on Ionis RNA medicines with neuroscience deal

  Sept. 27, 2023

• Intercept, after biotech rollercoaster ride, agrees to buyout by Alfasigma

  Sept. 26, 2023

• Novartis radiopharmaceutical drug succeeds in first-line gut cancer study

  Sept. 25, 2023

• AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors

  Sept. 22, 2023

• Novo Nordisk parent backs cell therapy manufacturing facility

  Sept. 21, 2023

• Alvotech gets new FDA review for Humira biosimilar

  Sept. 20, 2023

• Novartis cancels Beigene partnership as cancer drug gains EU approval

  Sept. 19, 2023

• Orchard nears FDA decision on rare disease gene therapy

  Sept. 18, 2023

• FTC takes aim at pharma patent tactics used to block generics

  Sept. 15, 2023

• FDA panel backs Alnylam drug despite doubts over benefit

  Sept. 13, 2023

• Daiichi Sankyo, with new data, to seek FDA approval of lung cancer drug

  Sept. 11, 2023

• Manufacturing delays under-the-skin Tecentriq shot in US

  Sept. 8, 2023

• Seagen partners with Nurix to create new kind of cancer drug

  Sept. 7, 2023

• FTC allows Amgen’s $28B deal for Horizon to go through, with conditions

  Sept. 1, 2023

• Novo, continuing deal streak, buys another obesity drug startup

  Aug. 30, 2023

• FTC pulls back on legal challenge to Amgen’s $28B bid for Horizon

  Aug. 28, 2023

• Novo, with new data, builds case for using Wegovy to protect heart health

  Aug. 25, 2023

• CVS launches new venture in biosimilar drug experiment

  Aug. 24, 2023

• Roche’s surprise study results spur new optimism for TIGIT drugs

  Aug. 23, 2023

• FDA partially halts leukemia studies of Gilead cancer drug

  Aug. 21, 2023

• Moderna builds case for updated COVID shot ahead of latest booster push

  Aug. 18, 2023

• Gilead antibody drug shows signs of potential in early lung cancer

  Aug. 17, 2023

• FDA lifts hold on Arcellx’s Gilead-partnered cancer cell therapy

  Aug. 15, 2023

• FDA approves bispecific drug from Pfizer for multiple myeloma

  Aug. 14, 2023

• A biotech scraps two cancer trials in latest setback for emerging drug class

  Aug. 11, 2023

• Novo hikes sales outlook on rising potential for obesity, diabetes drugs

  Aug. 10, 2023

• Regeneron ups genetic medicine investment with Decibel buyout

  Aug. 9, 2023

• Novo obesity drug protects heart health in large trial

  Aug. 8, 2023

• GSK broadens use of cancer immunotherapy with latest FDA OK

  Aug. 1, 2023

• Lilly adds to case for Mounjaro’s weight-loss benefits with new study data

  July 27, 2023

• Biosimilar makers split strategies in bid to take on top-selling Humira

  July 26, 2023

• Moderna, Merck advance cancer vaccine into late-stage test

  July 26, 2023

• Teva strengthens ties with biosimilar maker Alvotech

  July 24, 2023

• Novartis cancels BeiGene deal as questions over cancer drug target persist

  July 11, 2023

• European regulators probe suicide risk to Ozempic, other Novo drug Saxenda

  July 10, 2023

• Sarepta sells FDA fast pass earned from Duchenne gene therapy approval

  July 5, 2023

• Novartis, continuing revamp, sells eye drugs to Bausch + Lomb for up to $2.5B

  June 30, 2023

• Answering Roche, AbbVie and Genmab claim new study success for lymphoma drug

  June 28, 2023

• Pfizer’s PARP drug follows Lynparza with narrow clearance in prostate cancer

  June 21, 2023

• Patient death spurs FDA to pause test of Arcellx’s Gilead-partnered cell therapy

  June 20, 2023

• After years of disappointment, cancer vaccines show new promise

  June 8, 2023

• Closing ASCO: AstraZeneca’s ‘very special’ meeting, more CAR-T survival data and Pfizer’s PARP play

  June 6, 2023

• Novartis drug helps stop breast cancer’s return in large study

  June 2, 2023

• Pfizer says hemophilia drug succeeded in Phase 3 study

  May 30, 2023

• J&J antibody drug combination shows promise in multiple myeloma

  May 25, 2023

• Teva puts rival to Prometheus, Pfizer drugs at center of turnaround plans

  May 18, 2023

• FTC sues to block Amgen’s $27.8B deal for Horizon

  May 16, 2023

• Gilead expands Arcus partnership, with eye to inflammatory disease

  May 15, 2023

• Cancer vaccine from BioNTech, Roche shows potential in small study

  May 10, 2023

• Roche pays China-based biotech $70M for a new HER2 drug

  May 9, 2023

• FibroGen’s anemia pill falls short in blood cancer study

  May 5, 2023

• Novo reveals another setback in obesity drug’s launch

  May 4, 2023

• Lilly’s fortunes rise on back-to-back success for Alzheimer’s, obesity drugs

  May 4, 2023

• Lilly drug slows Alzheimer’s decline in large study

  May 3, 2023

• Pfizer turns focus to new drugs as COVID vaccine revenue falls

  May 2, 2023

• Lilly plans dash to market for weight loss drug after trial win

  April 27, 2023

• Lilly drug Mounjaro succeeds in second weight loss study

  April 27, 2023

• Bristol Myers’ Caforio stepping down as CEO in November

  April 26, 2023

• Roche’s new eye drug pressures Eylea with strong launch

  April 26, 2023

• Lilly sells emergency diabetes drug for $500M

  April 24, 2023

• French biotech pulls EMA application for eye disease gene therapy

  April 21, 2023

• FDA approves earlier use of Roche’s Polivy in common form of lymphoma

  April 20, 2023

• Nektar lays off more staff in effort to sustain operations

  April 18, 2023

• Moderna, Merck data support claim of cancer vaccine’s promise

  April 16, 2023

• FDA again knocks back Alvotech’s Humira biosimilar

  April 14, 2023

• New data raise more doubts about Moderna’s flu vaccine

  April 11, 2023

• Acquired patents aid J&J defense of top-selling drug from biosimilar challenge

  March 29, 2023

• Viking joins obesity drug development race with early study data

  March 28, 2023

• Novartis, following Lilly, claims success in early breast cancer study

  March 27, 2023

• U.S. government again rejects call to seize Xtandi rights

  March 22, 2023

• A biotech stumbles in its bid to challenge Novo’s obesity drug

  March 21, 2023

• Flush with cash, BioNTech buys into an immunotherapy to rival Yervoy

  March 20, 2023

• Merck TIGIT drug misses goal in lung cancer trial, adding to doubts over approach

  March 17, 2023

• In Pfizer-Seagen review, FTC has chance to set new pharma precedent

  March 14, 2023

• FDA advisers back earlier use of Roche lymphoma drug

  March 10, 2023

• Lilly reaches end of the road with long-studied Alzheimer’s drug

  March 9, 2023

• Merck pays $50 million for early-stage Epstein-Barr vaccine

  March 8, 2023

• Adaptimmune acquires struggling cell therapy rival following layoffs

  March 6, 2023

• Exelixis reports trial failure for cancer drug combination

  March 3, 2023

• FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs

  March 2, 2023

• Lilly to lower insulin prices by 70%

  March 1, 2023

• Merck reports two Phase 3 study misses for Keytruda

  Feb. 28, 2023

• Roche hands rights to lung cancer drug back to Blueprint

  Feb. 24, 2023

• Medicare maintains limits on Eisai’s new Alzheimer’s drug

  Feb. 23, 2023

• Doctors largely comfortable with biosimilar drugs, but question economics: report

  Feb. 22, 2023

• Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’

  Feb. 21, 2023

• Pfizer makes case for PARP-blocking drug in prostate cancer

  Feb. 17, 2023

• GSK backs away from COVID collaboration with Vir

  Feb. 14, 2023

• GSK wins full approval for cancer immunotherapy, looks to expand use

  Feb. 10, 2023

• FDA offers former biotech unicorn Intarcia a chance for a panel review

  Feb. 9, 2023

• Roche writes off $3B on lower sales forecasts for gene therapies, cancer drugs

  Feb. 3, 2023

• Lilly reports fast sales for new diabetes drug

  Feb. 2, 2023

• Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug

  Jan. 31, 2023

• FDA advisers back agency plan to simplify COVID-19 vaccination

  Jan. 26, 2023

• Lilly to boost diabetes drug production with $450M factory investment

  Jan. 24, 2023

• BeiGene wins expanded approval for leukemia drug, intensifying battle with AbbVie, AstraZeneca

  Jan. 20, 2023

• Roche says Tecentriq immunotherapy reduces risk of liver cancer recurrence

  Jan. 19, 2023

• Novo Nordisk diabetes pill wins FDA approval for first-line use

  Jan. 13, 2023

• Looking past Humira, AbbVie boosts sales forecasts for successor drugs

  Jan. 11, 2023

• JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies

  Jan. 10, 2023

• Arrowhead reports positive data from liver drug, but company’s shares slide

  Jan. 9, 2023

• 5 questions facing the pharma industry in 2023

  Jan. 9, 2023

• 5 FDA decisions to watch in the first quarter

  Jan. 9, 2023

• Pfizer pares back early-stage research in rare disease, cancer

  Jan. 6, 2023

• Novocure shares soar on positive lung cancer data

  Jan. 5, 2023

• Pharma companies boost drug prices to start year, but hikes lag inflation

  Jan. 3, 2023

• FDA approval of Biogen Alzheimer’s drug was ‘rife with irregularities,’ congressional report says

  Dec. 30, 2022

• FDA sets decision date for Alvotech’s Humira biosimilar

  Dec. 22, 2022

• Government spending bill would tighten FDA oversight of accelerated drug approvals

  Dec. 20, 2022

• Roche, Biogen sign royalty deal for late-stage lymphoma drug

  Dec. 19, 2022

• Lilly lays out ambitious plans for 2023

  Dec. 14, 2022

• Moderna vaccine succeeds in early-stage skin cancer study with Merck’s Keytruda

  Dec. 13, 2022

• Roche’s hemophilia gene therapy holds steady with longer-term data

  Dec. 12, 2022

• MEI, Kyowa stop lymphoma drug trials after FDA meeting

  Dec. 6, 2022

• Roche study failure gives Alzheimer’s researchers new clues in drug quest

  Dec. 1, 2022

• Roche pulls Tecentriq in bladder cancer, completing sweep of ‘dangling’ accelerated approvals

  Nov. 29, 2022

• FDA grants speedy review to Sarepta’s Duchenne gene therapy

  Nov. 28, 2022

• Teva taps Sandoz veteran to take over CEO post from Schultz

  Nov. 21, 2022

• For ImmunoGen, persistence pays off as FDA clears ovarian cancer drug

  Nov. 15, 2022

• Moderna data supports use of omicron booster over original vaccine

  Nov. 14, 2022

• Under FDA pressure, GSK limits use of ovarian cancer drug

  Nov. 11, 2022

• EQRx redraws ‘radical’ drug pricing plans for first two drugs

  Nov. 10, 2022

• Ipsen drug shows benefit in pancreatic cancer, lifting shares of ghost company

  Nov. 9, 2022

• Early data hint at benefit for Amgen’s obesity drug

  Nov. 8, 2022

• Novo obesity drug sales lag as manufacturing problems persist

  Nov. 2, 2022

• Pfizer gets first positive result for an RSV vaccine in pregnant women

  Nov. 1, 2022

• With positive trial results, Bristol Myers looks to widen use of blood disease drug

  Oct. 31, 2022

• Vaxcyte rides investor enthusiasm for early pneumococcal vaccine data

  Oct. 24, 2022

• AstraZeneca’s persistence pays off with Imjudo approval

  Oct. 24, 2022

• Speedy FDA approvals in focus as agency weighs withdrawal of preterm birth drug

  Oct. 21, 2022

• FDA advisers back withdrawal of controversial drug for preterm birth

  Oct. 19, 2022

• 5 questions facing drugmakers as third quarter earnings begin

  Oct. 17, 2022

• GSK sets high bar with trial results for RSV vaccine

  Oct. 13, 2022

• A young biotech’s shares soar on early psoriasis drug results

  Oct. 11, 2022

• Merck cardiovascular drug succeeds in study, validating $11B buyout bet

  Oct. 10, 2022

• PureTech, Nektar end talks of combination

  Oct. 7, 2022

• Lilly looks to speed FDA review of new diabetes drug in obesity

  Oct. 6, 2022

• Pfizer says PARP inhibitor succeeds in prostate cancer study

  Oct. 4, 2022

• 5 FDA decisions to watch in the fourth quarter

  Oct. 3, 2022

• Federal watchdog highlights flaws in speedy FDA approvals

  Sept. 30, 2022

• Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy

  Sept. 29, 2022

• Biogen, Eisai data raises hope for other experimental Alzheimer’s drugs

  Sept. 28, 2022

• In surprise result, Alzheimer’s drug from Eisai, Biogen shows benefit in large trial

  Sept. 27, 2022

• Roche pays $70M in another bid to catch up on cancer cell therapies

  Sept. 27, 2022

• GSK names Julie Brown, former Burberry executive, its first female CFO

  Sept. 26, 2022

• AstraZeneca gives up on Ionis’ RNA drug for heart disease

  Sept. 23, 2022

• Theravance, flush with royalty cash, buys shares from GSK

  Sept. 19, 2022

• Sanofi, AstraZeneca secure EMA support for RSV drug in babies

  Sept. 16, 2022

• Pfizer reports success in trial of all-in-one meningitis vaccine

  Sept. 15, 2022

• Pharmas back a startup’s plan to make CAR-T cells inside the body

  Sept. 14, 2022

• BioMarin reports cancer case in hemophilia gene therapy trial

  Sept. 13, 2022

• Bristol Myers gets FDA approval for new type of psoriasis drug

  Sept. 10, 2022

• FDA names new head to vaccine review office

  Sept. 9, 2022

• Gilead says its breast cancer drug helped patients live longer in study

  Sept. 8, 2022

• Can biosimilars, after years of limited impact, finally make a mark in the US?

  Sept. 7, 2022

• FDA holds back Alvotech’s Humira biosimilar over manufacturing issues

  Sept. 6, 2022

• With rare acquisition, Novo Nordisk makes $1B bet on sickle cell disease drug

  Sept. 1, 2022

• Jounce’s latest setback dampens outlook for another cancer immunotherapy target

  Aug. 30, 2022

• AstraZeneca, matching Lilly, reports positive heart failure data for diabetes pill

  Aug. 29, 2022

• Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology

  Aug. 26, 2022

• Novartis begins plans to spin off generic drug business

  Aug. 25, 2022

• Safety worries spur Novartis to suspend drug dosing in Huntington’s trial

  Aug. 24, 2022

• Gilead breaks through with first approval for new HIV drug

  Aug. 22, 2022

• Ventyx touts early data for potential rival to Bristol Myers psoriasis drug

  Aug. 16, 2022

• UK approves Moderna’s two-pronged COVID-19 booster

  Aug. 15, 2022

• Sarepta to ask FDA for accelerated approval of Duchenne gene therapy

  July 29, 2022

• Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug

  July 25, 2022

• Roche CEO Schwan, who guided company as cancer drug powerhouse, to step down next year

  July 21, 2022

• Roche digs deeper into gene therapy for the eye

  July 20, 2022

• Merck terminates Lynparza trial in colorectal cancer

  July 19, 2022

• Drug deals, launches in focus as pharma earnings begin

  July 18, 2022

• FDA clears Novavax’s COVID-19 vaccine as 4th option in US

  July 13, 2022

• Healthcare asset manager Innoviva buys another biotech at a bargain price

  July 11, 2022

• AbbVie dials back partnership on experimental Alzheimer's drug

  July 8, 2022

• As Merck closes in on Seagen, the FTC nears a key test on pharma deals

  July 7, 2022

• FDA, under fire for Aduhelm approval, starts review of another Alzheimer's drug

  July 6, 2022

• CureVac sues rival COVID-19 vaccine maker BioNTech for patent infringement

  July 5, 2022

• FDA halts tests of Sanofi drug, acquired in $3.7B buyout, due to side effects

  June 30, 2022

• 5 FDA decisions to watch in the third quarter

  June 29, 2022

• Pfizer, Roivant spin out new company to advance anti-inflammatory drugs

  June 28, 2022

• Ipsen adds to cancer business with bargain buyout of Epizyme

  June 27, 2022

• Sanofi, GSK say dual-acting vaccine prevents COVID-19 from omicron in large trial

  June 24, 2022

• UniQure buoyed by early data for Huntington's gene therapy

  June 23, 2022

• Pfizer takes stake in Lyme disease partner ahead of key study

  June 21, 2022

• Pharma under the microscope as FTC considers new ways to review acquisitions

  June 16, 2022

• FDA staff supportive of Pfizer, Moderna COVID vaccines in young children

  June 13, 2022

• GSK claims first positive Phase 3 result for an RSV vaccine

  June 10, 2022

• Alnylam follows rivals with new study results for kidney disease drug

  June 9, 2022

• FDA advisers back Novavax's latecomer COVID-19 vaccine

  June 7, 2022

• Roche keeps the faith in new cancer immunotherapy despite trial setbacks

  June 7, 2022

• Bristol Myers bets $4B on Turning Point and its targeted cancer drugs

  June 3, 2022

• Regeneron buys control of cancer drug Libtayo from Sanofi

  June 2, 2022

• Bristol Myers' autoimmune drug shows potential in lupus

  June 1, 2022

• Roche SMA drug approved in youngest infants, challenging Novartis and Biogen

  May 31, 2022

• Merck study results signal blood cancer potential for new type of immunotherapy

  May 26, 2022

• Pfizer pledges not-for-profit sale of medicines in low-income countries

  May 25, 2022

• Responding to outbreak, Moderna starts early work on monkeypox vaccine

  May 24, 2022

• Pfizer says 3 doses of its COVID-19 vaccine works in youngest children

  May 23, 2022

• PTC's first gene therapy gains European regulator's backing

  May 20, 2022

• Trial setback casts doubt on a biotech's respiratory virus drug

  May 19, 2022

• Scientists home in on cause of Duchenne gene therapy side effect

  May 17, 2022

• Lilly wins FDA approval for new kind of diabetes drug

  May 13, 2022

• NIH licenses COVID-19 technologies to WHO-backed program

  May 13, 2022

• Key Bristol Myers drug holds up in long-term psoriasis study

  May 12, 2022

• With spotlight on FDA, Congress weighs reforms to accelerated drug approvals

  May 10, 2022

• Pfizer cleared to restart hemophilia gene therapy trial

  May 3, 2022

• FDA rejects two China-developed cancer drugs

  May 2, 2022

• Bristol Myers wins FDA approval for first drug to treat inherited heart condition

  April 28, 2022

• Lilly's closely watched diabetes drug scores in obesity trial

  April 28, 2022

• Solid Bio joins slate of biotech layoffs, shedding 35% of its workforce

  April 27, 2022

• Nektar begins sweeping layoffs after $2B Bristol Myers deal falls apart

  April 26, 2022

• Roche stumbles in latest setback for an emerging group of breast cancer drugs

  April 25, 2022

• FDA panel supports agency push to raise approval bar for certain cancer drugs

  April 22, 2022

• J&J cuts COVID vaccine sales forecasts, citing high supplies and lagging demand

  April 19, 2022

• Bristol Myers scraps $2B Nektar partnership after trial failures

  April 18, 2022

• AbbVie, Genmab, with new data, prep FDA application for dual-acting cancer drug

  April 14, 2022

• UK bid to battle antibiotic resistance yields first subscription-style plan

  April 12, 2022

• Pfizer, Moderna name new finance chiefs amid surging revenue

  April 11, 2022

• Medicare finalizes policy limiting coverage of Biogen Alzheimer's drug

  April 7, 2022

• FDA rejects Akebia drug, dealing another blow to anemia pills

  March 30, 2022

• Adagio plans comeback for COVID drug, but is it too late?

  March 30, 2022

• Biogen shelves ALS drug after early-stage trial failure

  March 28, 2022

• FDA rebuffs MEI, Kyowa Kirin as another cancer drug class draws scrutiny

  March 25, 2022

• Argenx boosted by positive trial results for new shot

  March 22, 2022

• Two decades and $200 billion: AbbVie’s Humira monopoly nears its end

  March 17, 2022

• With trial success in kidney disease, Lilly, Boehringer make case for broader use of diabetes drug

  March 16, 2022

• BridgeBio looks for comeback with trial results for muscular dystrophy drug

  March 14, 2022

• Moderna extends patent waiver for COVID vaccine, but only for lower-income countries

  March 8, 2022

• Bluebird's CFO resigns as cash woes raise doubts about its future

  March 7, 2022

• Roche, nearing major trial readouts, starts new Alzheimer's drug study

  March 3, 2022

• Gene editing biotechs face new uncertainty after CRISPR patent ruling

  March 2, 2022

• FDA rejects Reata drug for rare kidney disease

  Feb. 28, 2022

• Lilly, Boehringer diabetes pill wins expanded use in heart failure

  Feb. 25, 2022

• Moderna bets on booster demand, advancing new 'bivalent' COVID-19 shot

  Feb. 24, 2022

• Sanofi and GSK, after delays, to seek clearance for COVID-19 vaccine

  Feb. 23, 2022

• Moderna, on the heels of pharma rivals, cleared to advance RSV vaccine

  Feb. 22, 2022

• Citing safety signal, GSK pauses some trials of new RSV vaccine

  Feb. 18, 2022

• Califf confirmed as FDA chief in close vote, ending protracted vacancy at health agency

  Feb. 15, 2022

• Lilly's new COVID-19 antibody becomes US' latest tool to battle omicron

  Feb. 11, 2022

• FDA sends signal with tough questions of Lilly at cancer drug meeting

  Feb. 10, 2022

• Why the FDA is making a test case of a cancer drug from China

  Feb. 8, 2022

• Sanofi's Bioverativ deal begins to pay dividends with first new drug approval

  Feb. 7, 2022

• Lilly slows FDA submission of Alzheimer's drug after Medicare decision

  Feb. 3, 2022

• Pfizer lures research chief from Roche, prompting high-level reshuffle

  Feb. 1, 2022

• The pipeline of new antibiotics is drying up. A bill in Congress aims to change that.

  Feb. 1, 2022

• Roche wins FDA approval for rival to Regeneron's lucrative eye drug

  Jan. 31, 2022

• Regeneron, Sanofi are latest to withdraw a cancer drug application

  Jan. 28, 2022

• Moderna follows Pfizer in beginning trial of omicron vaccine

  Jan. 26, 2022

• A biotech wins the first FDA drug approval in a rare type of eye cancer

  Jan. 26, 2022

• Generic manufacturers sign pact to supply Merck COVID pill to lower-income countries

  Jan. 20, 2022

• GSK loses R&D chief Barron to high-powered startup amid investor pressure

  Jan. 19, 2022

• Roche revives a closely watched Huntington's disease drug

  Jan. 18, 2022

• Medicare faces blowback over plan to limit coverage of Biogen's Alzheimer's drug

  Jan. 14, 2022

• Medicare proposes to limit coverage of Biogen Alzheimer's drug

  Jan. 11, 2022

• 5 questions facing the FDA in 2022

  Jan. 11, 2022

• JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies

  Jan. 10, 2022

• After years of decline, drugmakers' price hikes may have bottomed out

  Jan. 5, 2022

• Novartis wins FDA approval for new heart drug, but faces uphill sales battle

  Dec. 22, 2021

• COVID-19 pills from Pfizer, Merck authorized by FDA in major pandemic milestone

  Dec. 22, 2021

• Novartis ups investment in gene therapy for the eye with $800M buyout

  Dec. 22, 2021

• Duchenne patient dies in Pfizer gene therapy study

  Dec. 21, 2021

• Moderna vaccine weaker against omicron, but third shot boosts protection

  Dec. 20, 2021

• J&J's coronavirus vaccine faces new US limits

  Dec. 16, 2021

• Rebounding from setbacks, Sanofi reveals promising data for hemophilia drug

  Dec. 14, 2021

• Vaccine from Medicago, GSK protective against COVID-19 in large study

  Dec. 7, 2021

• Lilly drug becomes first COVID antibody cleared for use in young children

  Dec. 6, 2021

• Novartis pays $150M for access to UCB's Parkinson's drug

  Dec. 2, 2021

• FDA panel, after debate, narrowly backs Merck COVID pill

  Nov. 30, 2021

• Blueprint, taking aim at larger drugmakers, becomes a biotech buyer

  Nov. 29, 2021

• AstraZeneca, after years of delays, opens UK hub meant to recharge drug research

  Nov. 23, 2021

• Gilead pays up to retain rights to Arcus cancer drugs

  Nov. 18, 2021

• European drugs regulator signals rejection likely for Biogen's Aduhelm

  Nov. 17, 2021

• As Congress weighs drug price restraints, ICER calls out 'unsupported' increases

  Nov. 16, 2021

• Anticipating Aduhelm's costs, Medicare plans big jump in premiums

  Nov. 15, 2021

• Biden nominates Robert Califf to return as FDA head

  Nov. 12, 2021

• Moderna, escalating dispute with NIH, claims government had no role in key vaccine patent

  Nov. 11, 2021

• Detailed Roche study results muddy another Alzheimer's hypothesis

  Nov. 11, 2021

• Pfizer again asks FDA to authorize COVID-19 boosters for all adults

  Nov. 9, 2021

• Eye-focused gene therapy startup gets $60M cash infusion from Sanofi

  Nov. 8, 2021

• Pfizer pill for COVID-19 shows dramatic benefit in major study finding

  Nov. 5, 2021

• Democrats’ drug pricing plan, while scaled back, could still squeeze pharma top-sellers

  Nov. 4, 2021

• FDA extends review of J&J, Legend's cell therapy for multiple myeloma

  Nov. 2, 2021

• A three-decade monopoly: how Amgen built a patent thicket around its top-selling drug

  Nov. 1, 2021

• Drug price restraints dropped as Biden prioritizes other measures

  Oct. 29, 2021

• Merck sees up to $7B in coming sales of coronavirus pill

  Oct. 28, 2021

• A play-by-play of the FDA's meeting on Pfizer's vaccine for kids

  Oct. 26, 2021

• Moderna vaccine safe and spurs immune response in kids, company says

  Oct. 25, 2021

• CDC panel backs COVID-19 boosters for Moderna, J&J vaccine recipients

  Oct. 21, 2021

• Atea, Roche change plans for oral COVID-19 drug after trial setback

  Oct. 19, 2021

• Esperion lays off nearly half its workforce as heart drug sales disappoint

  Oct. 18, 2021

• CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T

  Oct. 12, 2021

• Adamas, Flexion sell for $825M combined as biotech's dealmaking pace picks up

  Oct. 11, 2021

• Gene therapy developer gets chance at a comeback with Pfizer deal

  Oct. 6, 2021

• Collins to step down as NIH head in transition for research agency

  Oct. 5, 2021

• J&J heats up RSV race with new vaccine data

  Oct. 4, 2021

• 5 FDA approval decisions to watch in the fourth quarter

  Oct. 1, 2021

• Sanofi claims positive early data for mRNA COVID shot, but pivots to flu instead

  Sept. 28, 2021

• As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

  Sept. 27, 2021

• Chinese drugmaker Clover says vaccine prevents COVID-19 in large trial

  Sept. 22, 2021

• Seagen, Genmab win speedy FDA approval for cervical cancer drug

  Sept. 21, 2021

• Pfizer says coronavirus vaccine is safe and spurs immune response in children

  Sept. 20, 2021

• Biogen says experimental pain drug helps neuropathy patients in mid-stage trial

  Sept. 17, 2021

• New data from Israel, Pfizer show potent effect from third coronavirus shot

  Sept. 15, 2021

• Biden pushes forward on Medicare price negotiation

  Sept. 10, 2021

• Sanofi drug for rare skin disease, acquired in buyout, fails in late-stage trial

  Sept. 9, 2021

• Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

  Sept. 7, 2021

• Settling lawsuit, AstraZeneca and European Commission agree on coronavirus vaccine delivery

  Sept. 3, 2021

• After coronavirus success, J&J hits setback with HIV vaccine

  Aug. 31, 2021

• FDA scrutiny, Merck approval lead Roche to pull Tecentriq in breast cancer

  Aug. 30, 2021

• With new results, J&J's $1B gamble on a targeted inflammation drug faces long odds

  Aug. 24, 2021

• FDA grants full approval to Pfizer, BioNTech's coronavirus vaccine

  Aug. 23, 2021

• Biden said to rule out Woodcock as permanent FDA chief

  Aug. 20, 2021

• Lilly, preparing Alzheimer's drug plans, forms new neuroscience unit in company restructure

  Aug. 17, 2021

• Biden embraces Medicare drug price negotiation as Democrats seek to widen health coverage

  Aug. 12, 2021

• Eyeing future outbreaks, Moderna partners with Canadian government on vaccine plant

  Aug. 10, 2021

• Roche sets bar in early lymphoma treatment with Polivy study results

  Aug. 9, 2021

• Regeneron drug extends survival in lung cancer trial, lifting company's hopes in field

  Aug. 5, 2021

• FDA allows Novartis gene therapy trials to resume after nearly 2 year pause

  Aug. 3, 2021

• AstraZeneca wins first FDA approval for systemic lupus drug in a decade

  Aug. 2, 2021

• Pfizer's fast progress shines spotlight on an emerging vaccine race

  July 30, 2021

• In a first, FDA approves an 'interchangeable' biosimilar for diabetes

  July 29, 2021

• An AstraZeneca spinout scores a buyout option from Arena

  July 27, 2021

• Regeneron, AstraZeneca team up on targeted drugs for obesity

  July 27, 2021

• BioNTech, WHO hatch plan to bring mRNA vaccines to Africa

  July 26, 2021

• Biogen executives attack Aduhelm criticism, blaming 'extensive misinformation'

  July 22, 2021

• Pfizer, BioNTech ink vaccine supply deal for Africa in step toward addressing criticism

  July 21, 2021

• Merck to take on Pfizer with FDA OK of next-gen pneumonia vaccine

  July 19, 2021

• FDA advisers push back on FibroGen anemia drug

  July 16, 2021

• Lilly wagers up to $1B on a biotech's plan for a new type of insulin

  July 14, 2021

• FDA flags rare side effect in new warning on J&J's coronavirus vaccine

  July 12, 2021

• Alzheimer's Association, insurers press Medicare for coverage rules on Aduhelm

  July 12, 2021

• Sanofi dives deeper into mRNA in search for next-generation vaccines

  June 29, 2021

• Congress pressures FDA and Biogen on Alzheimer's drug approval, price

  June 28, 2021

• GSK outlines ambitious 10-year plan, but hits investors' near-term outlook

  June 23, 2021

• Merck says Keytruda extends survival in cervical cancer study

  June 22, 2021

• Long-term Zolgensma data backs up gene therapy's use in youngest patients

  June 21, 2021

• Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody

  June 18, 2021

• Trial failure dashes Biogen hopes for next Alzheimer's drug

  June 17, 2021

• Former FDA chief Hahn joins venture firm that launched Moderna

  June 15, 2021

• CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorder

  June 15, 2021

• As trials progress, FDA weighs COVID-19 vaccine authorizations for children

  June 11, 2021

• 'The lights are no longer green': Antitrust regulators reassess pharma deals

  June 10, 2021

• Biogen Alzheimer's approval could open the door for similar drugs

  June 9, 2021

• Novo keeps price in line with FDA approval of second obesity shot

  June 7, 2021

• Alexion, AstraZeneca executives switch roles amid $39B buyout

  June 4, 2021

• Former FDA official Abernethy joins Google health spinoff

  June 3, 2021

• UniQure moves Huntington's gene therapy to next phase of key trial

  May 27, 2021

• ICER, vocal critic of drug company pricing, turns scrutiny to insurers

  May 25, 2021

• J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies

  May 24, 2021

• Humira patents take center stage as House panel targets AbbVie pricing

  May 18, 2021

• Trump tax law cut what US drugmakers owed. Now they fear an increase.

  May 17, 2021

• Pfizer, BioNTech are first to seek full FDA approval of a coronavirus vaccine

  May 7, 2021

• Pharma erupts as Biden administration backs waiver of vaccine patent rights

  May 6, 2021

• Dyno, in demand for its gene therapy work, raises $100M for fast expansion

  May 6, 2021

• Esker, a new biotech startup, launches with plans to make targeted immune drugs

  May 5, 2021

• Sarepta's second-gen Duchenne drug shows signs of topping its first

  May 3, 2021

• Denying problems, AstraZeneca says US coronavirus vaccine filing due within weeks

  April 30, 2021

• Moderna plans to triple coronavirus vaccine production next year

  April 29, 2021

• Lilly, citing FDA feedback, won't seek speedy approval of Alzheimer's drug

  April 27, 2021

• FDA lifts hold on UniQure gene therapy study after review of cancer case

  April 26, 2021

• A look ahead at the FDA meeting that could decide the future of 6 cancer drug approvals

  April 22, 2021

• J&J to resume vaccine rollout in Europe after regulator says benefits outweigh risks

  April 20, 2021

• Positive data in hand, TG Therapeutics readies MS drug for FDA review

  April 19, 2021

• US clears AstraZeneca buyout of Alexion amid closer scrutiny of biopharma M&A

  April 16, 2021

• CDC panel delays decision on J&J vaccine, extending pause over rare side effect

  April 14, 2021

• The US paused use of J&J's vaccine. What happens next?

  April 13, 2021

• Cavazzoni to succeed Woodcock as the FDA's top drug reviewer

  April 12, 2021

• Sage, Biogen drug reduces tremors but side effects could limit potential

  April 12, 2021

• Pfizer, BioNTech's vaccine protects 12- to 15-year-olds from COVID-19 in study

  March 31, 2021

• 5 FDA approval decisions to watch in the second quarter

  March 29, 2021

• Bristol Myers gets late-stage win in test of new type of immunotherapy

  March 25, 2021

• Roche stops giving Huntington's disease drug in closely watched study

  March 23, 2021

• Roche immunotherapy notches a win in early lung cancer, pressuring Merck

  March 22, 2021

• With new results, Sarepta's 2nd gene therapy holds steady

  March 19, 2021

• Gilead, still aiming at NASH, broadens an alliance with Novo

  March 18, 2021

• FTC joins overseas antitrust regulators in reexamination of pharma M&A

  March 16, 2021

• Lilly lays out 2-year plan to gain approval for Alzheimer's drug

  March 15, 2021

• Detailed Lilly data give mixed picture of Alzheimer's drug's benefit

  March 13, 2021

• The top drugs that could be impacted by an obscure provision in the pandemic relief law

  March 12, 2021

• Novartis bid to bring rare disease drug to lung cancer hits a roadblock

  March 9, 2021

• Spurred by FDA review, Roche pulls Tecentriq for bladder cancer use

  March 8, 2021

• Countering payers, drugmakers say net prices declined in 2020

  March 5, 2021

• Lilly says diabetes shot outperformed rival Novo drug in study

  March 4, 2021

• Vir shares tumble after apparent setback for COVID-19 drug

  March 3, 2021

• Merck to help J&J make vaccine doses in White House-brokered deal

  March 2, 2021

• A play-by-play of the FDA meeting on J&J's vaccine

  Feb. 26, 2021

• Moderna, Pfizer ready multi-pronged plans for coronavirus variants

  Feb. 24, 2021

• FDA review supports safety, efficacy of J&J coronavirus vaccine

  Feb. 24, 2021

• AstraZeneca withdraws immunotherapy in bladder cancer after trial failure

  Feb. 22, 2021

• Pfizer, BioNTech ask FDA approval to ease temperature requirements for coronavirus shot

  Feb. 19, 2021

• Novartis expects sales lift from expanded heart drug approval

  Feb. 17, 2021

• FDA approves Regeneron drug for rare genetic form of high cholesterol

  Feb. 12, 2021

• AstraZeneca plans for adapting vaccine to coronavirus variants, but offers longer timeline than rivals

  Feb. 11, 2021

• Small biotech gets big win on treatment for rare swelling disorder

  Feb. 9, 2021

• As COVID-19 becomes a business, vaccine makers confront thorny pricing questions

  Feb. 9, 2021

• PTC aims again for FDA review of Duchenne drug despite latest miss

  Feb. 5, 2021

• GSK expands CureVac vaccine partnership, changing course after setbacks

  Feb. 3, 2021

• Shifting strategy, Coherus buys rights to experimental cancer drug

  Feb. 1, 2021

• Novavax vaccine prevents COVID-19 in studies, but less effective against new variants

  Jan. 28, 2021

• Vaccine makers prepare response as coronavirus mutations raise alarms

  Jan. 28, 2021

• AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica

  Jan. 25, 2021

• Woodcock steps in as acting FDA chief with crucial vaccine decisions ahead

  Jan. 21, 2021

• Pfizer, BioNTech say vaccine effective against fast-spreading UK coronavirus variant

  Jan. 20, 2021

• Cancer-focused biotech turns its tools to building a 2nd-generation coronavirus vaccine

  Jan. 19, 2021

• Former FDA chief Kessler tapped as top Biden adviser for COVID-19 response

  Jan. 15, 2021

• 5 questions facing the FDA in 2021

  Jan. 14, 2021

• JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

  Jan. 12, 2021

• JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining

  Jan. 11, 2021

• Celgene's cell therapy spinout nets $292M from blank-check merger

  Jan. 8, 2021

• Sarepta gene therapy misses goal in key muscular dystrophy study

  Jan. 7, 2021

• Pfizer beats Sarepta to start of first late-stage Duchenne gene therapy trial

  Jan. 7, 2021

• Leading $105M biotech funding, Bayer deepens cell therapy investment

  Jan. 6, 2021

• 5 FDA approval decisions to watch in the 1st quarter

  Jan. 5, 2021

• AbbVie, Biogen lead pharma in new year's drug price hikes

  Jan. 4, 2021

• Merck signs $356M deal to supply US with experimental coronavirus drug

  Dec. 23, 2020

• With biosimilars looming, Roche makes case for new biologic eye drug

  Dec. 21, 2020

• A play-by-play of the FDA meeting on Moderna's coronavirus vaccine

  Dec. 17, 2020

• With trial plans, Novo wagers its diabetes drug can help treat Alzheimer's

  Dec. 16, 2020

• Lilly pays $880M for Prevail, pushing further into genetic medicine

  Dec. 15, 2020

• In historic decision, FDA clears coronavirus vaccine from Pfizer, BioNTech

  Dec. 11, 2020

• Lilly reports strong results for next-generation diabetes drug

  Dec. 9, 2020

• A play-by-play of the historic FDA meeting on Pfizer and BioNTech's coronavirus vaccine

  Dec. 9, 2020

• Researchers of the Year: The RECOVERY team

  Dec. 9, 2020

• In multiple myeloma, cell therapies lead but antibody drugs could follow fast

  Dec. 8, 2020

• J&J study finds multiple myeloma cell therapy to be strongly effective

  Dec. 5, 2020

• UK drug regulator is first to clear Pfizer, BioNTech's coronavirus vaccine

  Dec. 2, 2020

• CDC panel recommends giving first coronavirus vaccines to healthcare workers, nursing home residents

  Dec. 1, 2020

• Amgen cuts Cytokinetics loose after heart drug disappointment

  Nov. 23, 2020

• Trump administration pushes last-ditch plans to lower drug prices

  Nov. 20, 2020

• WHO recommends against Gilead's Veklury, in break with US guidelines

  Nov. 20, 2020

• FDA delays decision on Bristol Myers cell therapy, putting Celgene deal payouts in jeopardy

  Nov. 17, 2020

• Moderna's vaccine can last for weeks in a refrigerator, expanding an edge on rivals

  Nov. 16, 2020

• UCB strikes 2 gene therapy deals to build its pipeline

  Nov. 12, 2020

• Pfizer, BioNTech's strong results give lift to other coronavirus vaccines

  Nov. 11, 2020

• Coronavirus vaccine from Pfizer, BioNTech prevents COVID-19, early results show

  Nov. 9, 2020

• FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt

  Nov. 6, 2020

• FDA gene therapy holdups suggest closer scrutiny by agency

  Nov. 5, 2020

• Who would get Regeneron's COVID-19 antibody treatment?

  Nov. 5, 2020

• In 2020 election, an uncertain fate for drug price controls

  Nov. 3, 2020

• Revamp pays off for Kiadis with $358M Sanofi buyout

  Nov. 2, 2020

• Mirati cancer drug results spark hopes of outperforming Amgen's

  Oct. 26, 2020

• 5 takeaways from the FDA's closely watched coronavirus vaccine meeting

  Oct. 24, 2020

• Facing vaccine doubts, US grapples with building confidence in coronavirus shots

  Oct. 22, 2020

• CRISPR Therapeutics reports remissions, one death in cancer cell therapy study

  Oct. 21, 2020

• 5 questions ahead of this week's FDA meeting on coronavirus vaccines

  Oct. 16, 2020

• FDA puts Voyager study on hold in latest gene therapy speed bump

  Oct. 13, 2020

• Moderna says it won't enforce coronavirus vaccine patents during pandemic

  Oct. 8, 2020

• Pfizer and Sangamo, after rival's setback, kick off late-stage gene therapy trial

  Oct. 7, 2020

• FDA releases coronavirus vaccine guidelines that White House resisted

  Oct. 6, 2020

• Vir, GSK keep pace with rivals as COVID-19 antibody drugs grab spotlight

  Oct. 6, 2020

• From no drugs to 3: Patients with spinal muscular atrophy now face hard choices

  Oct. 5, 2020

• Solid gets all-clear from FDA to restart gene therapy trial

  Oct. 1, 2020

• Ironwood lays off one-third of staff after heartburn drug falls short in study

  Sept. 29, 2020

• FDA delays testing of Inovio's coronavirus vaccine

  Sept. 28, 2020

• Trump forges ahead with drug import plan, but impact in doubt

  Sept. 25, 2020

• Gene therapy company Taysha completes sprint from first funding to IPO

  Sept. 24, 2020

• AC Immune drug fails in blow to another Alzheimer's hypothesis

  Sept. 23, 2020

• FDA decision on Bristol Myers cell therapy could come down to the wire

  Sept. 22, 2020

• Seattle Genetics stays step ahead of rivals with bladder cancer data

  Sept. 18, 2020

• What to watch as the first late-stage coronavirus vaccine trials near potential readouts

  Sept. 17, 2020

• Arrowhead shares soar on liver disease data from four patients

  Sept. 16, 2020

• Novavax boosts coronavirus vaccine manufacturing capacity as key trial nears

  Sept. 15, 2020

• Trump releases long-awaited drug price order, but effects are likely far off

  Sept. 14, 2020

• Merck takes aim at Pfizer with pneumonia vaccine data

  Sept. 9, 2020

• Merck details cough drug data, raising questions about its potential

  Sept. 8, 2020

• Researchers publish first data on coronavirus vaccine approved by Russia

  Sept. 4, 2020

• Healthcare workers likely to be first in line for coronavirus vaccination

  Sept. 1, 2020

• Sanofi ends research of arthritis drug as coronavirus treatment

  Sept. 1, 2020

• Vir, GSK push coronavirus antibody drug straight into mid-stage tests

  Aug. 31, 2020

• CanSino said to seek early authorization of coronavirus vaccine

  Aug. 28, 2020

• Moderna's vaccine may have an edge when immunization programs roll out

  Aug. 26, 2020

• Moderna says its coronavirus vaccine sparks immune response in older people

  Aug. 26, 2020

• Sarepta, after two dramatic approvals, gets an FDA review for next Duchenne drug

  Aug. 25, 2020

• Moderna joins other vaccine leaders in European supply talks

  Aug. 24, 2020

• Coronavirus vaccine Pfizer, BioNTech chose for late-stage testing appears safer than first

  Aug. 20, 2020

• Momenta shift to new drugs pays off with $6.5B buyout by J&J

  Aug. 19, 2020

• Gilead expands Tango alliance, continuing a busy year of cancer deals

  Aug. 18, 2020

• Roche wins FDA approval for first self-administered biologic for rare eye disease

  Aug. 17, 2020

• AstraZeneca signals it won't wait for US data to seek clearance of coronavirus vaccine

  July 30, 2020

• Trump invites high-stakes showdown with big pharma as election looms

  July 28, 2020

• Moderna, pacing a global vaccine race, loses a key patent fight

  July 24, 2020

• Coronavirus vaccines speed ahead, but experts fear not everyone will take them

  July 23, 2020

• Pfizer and BioNTech coronavirus vaccine gets boost from German data

  July 20, 2020

• Side effects don't stop FDA panel from backing GSK blood cancer drug

  July 15, 2020

• Preventive studies for Eisai, Biogen Alzheimer's drug could add years to amyloid debate

  July 14, 2020

• Spark, chasing BioMarin, plans 2021 start for key hemophilia gene therapy study

  July 13, 2020

• FDA documents reveal doubts about GSK blood cancer drug

  July 10, 2020

• 5 FDA approval decisions to watch in the 3rd quarter

  July 8, 2020

• US buys up early supply of Regeneron's COVID-19 antibody cocktail

  July 7, 2020

• Regeneron advances COVID-19 antibody cocktail into late-stage trials

  July 6, 2020

• Federal coronavirus contracts dodge pricing oversight, advocacy group says

  July 1, 2020

• Without data, Inovio says study shows positive results for coronavirus vaccine

  June 30, 2020

• Former BARDA director claims HHS leaders tried to 'thwart' him in new role

  June 26, 2020

• Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says

  June 24, 2020

• By $4M, La Jolla outbids Melinta for struggling Tetraphase

  June 24, 2020

• Gilead, in latest cancer bet, puts $275M into immunotherapy startup Pionyr

  June 23, 2020

• Vaccines can end the coronavirus pandemic. Will every country get them?

  June 23, 2020

• NIH ends key COVID-19 studies of hydroxychloroquine

  June 22, 2020

• UniQure gets out the gate first in race for Huntington's gene therapy

  June 19, 2020

• With new proposal, Trump administration tries to encourage 'value-based' drug deals

  June 18, 2020

• Cheap steroid lowers risk of death in hospitalized COVID-19 patients, U.K. study finds

  June 16, 2020

• CureVac gets German backing for coronavirus vaccine, but says it's independent

  June 15, 2020

• AstraZeneca spinout wins first FDA approval 2 years after launch

  June 12, 2020

• Pressure on generic drugmakers increases with new price fixing lawsuit

  June 10, 2020

• Drug regulators in agreement on coronavirus vaccine trials, FDA official says

  June 9, 2020

• China's Innovent buys rights to Roche cancer technology

  June 9, 2020

• Coronavirus vaccines are rolling out quickly. Here's where the pipeline stands.

  June 9, 2020

• Alnylam details data for kidney disease drug under FDA review

  June 8, 2020

• AstraZeneca reaches deals with health charities to supply coronavirus vaccine worldwide

  June 4, 2020

• Hydroxychloroquine offers no COVID-19 protection after exposure, study shows

  June 3, 2020

• COVID-19 studies of malaria, blood pressure pills come under scrutiny

  June 3, 2020

• Bristol Myers follows Zeposia launch with positive data from key study

  June 2, 2020

• Regeneron expands Intellia gene editing deal as its post-Sanofi future emerges

  June 1, 2020

• AstraZeneca bid to expand lung cancer drug's use boosted by trial data

  May 28, 2020

• Novartis teams with Mass. Eye & Ear to join coronavirus vaccine chase

  May 28, 2020

• With $11B stock sale, Sanofi loosens ties with Regeneron

  May 26, 2020

• Intercept shares fall as FDA again delays closely watched NASH drug

  May 22, 2020

• Bangladesh pharma claims to be first to launch generic remdesivir

  May 21, 2020

• More questions than answers as Moderna's coronavirus vaccine speeds ahead

  May 19, 2020

• Ousted BARDA director: Hydroxychloroquine push distracted government scientists

  May 14, 2020

• J&J myeloma data heat up cell therapy battle

  May 13, 2020

• Activist investor pushes Alexion to sell after Portola deal

  May 12, 2020

• Dyno spins out of Harvard's laboratories with an aim to make gene therapy better

  May 11, 2020

• Novartis wins approval for niche lung cancer drug

  May 7, 2020

• After donation to the U.S., Gilead outlines plans to distribute COVID-19 drug worldwide

  May 6, 2020

• Pfizer, BioNTech launch U.S. trial of coronavirus vaccine

  May 5, 2020

• A coronavirus vaccine may arrive next year. 'Herd immunity' will take longer.

  May 4, 2020

• Texas university spins out Taysha, a gene therapy startup with 15 programs

  April 29, 2020

• Pfizer resumes trial recruitment suspended by coronavirus

  April 28, 2020

• Repurposed arthritis drug disappoints in closely watched COVID-19 trial

  April 27, 2020

• Malaria drug's potential against coronavirus dims as data mounts

  April 22, 2020

• Trial data help small biotech ready its anti-itch drug for approval

  April 21, 2020

• Positive data keep Bristol Myers and Exelixis in the kidney cancer race

  April 20, 2020

• Vir reminds biopharma its original aim is hepatitis B

  April 16, 2020

• J&J cuts sales forecast by $7B as coronavirus impact hits

  April 14, 2020

• AstraZeneca and Merck drug wins approval for rare cancer after failing elsewhere

  April 13, 2020

• Eye drug side effects are real, Novartis confirms in new warning

  April 9, 2020

• Myokardia at inflection point as heart drug readout nears

  April 9, 2020

• FDA delays decision on Roche spinal muscular atrophy drug

  April 7, 2020

• GSK bets $250M on Vir's antibody approach to treating coronavirus

  April 6, 2020

• Contamination concerns spur FDA call for nationwide withdrawal of heartburn drug

  April 1, 2020

• Under pressure, FDA touts speedy coronavirus drug development

  April 1, 2020

• Drugmakers await reckoning as doctors, patients make tough choices during pandemic

  April 1, 2020

• With latest FDA submission, Bristol Myers keeps pace with Celgene milestones

  March 31, 2020

• Merck's search for growth outside Keytruda may not end in heart disease

  March 30, 2020

• Sanofi adds mRNA to coronavirus vaccine push

  March 27, 2020

• Bristol Myers investors breathe easier as multiple sclerosis drug approved by FDA

  March 26, 2020

• In rare move, Gilead gives up 'orphan' status for experimental coronavirus drug

  March 25, 2020

• Leukemia drug from Roche, AbbVie extends survival, study finds

  March 23, 2020

• Remdesivir, chloroquine move to forefront as White House tries to speed coronavirus response

  March 19, 2020

• No White House offer for coronavirus vaccine access, CureVac says

  March 17, 2020

• Big pharma shied away from gene therapy for years. Academia picked up the slack

  March 17, 2020

• Regeneron and Sanofi speed Kevzara into coronavirus trials

  March 16, 2020

• New sickle cell drugs priced too high, ICER says

  March 13, 2020

• AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer

  March 12, 2020

• Coronavirus spread prompts FDA to postpone nearly all overseas inspections

  March 10, 2020

• Gates, Wellcome hatch $125M plan to speed coronavirus treatments

  March 10, 2020

• FDA, FTC put drugmakers on notice about tactics to block biosimilars

  March 9, 2020

• AstraZeneca immunotherapy combination falls short in bladder cancer trial

  March 6, 2020

• Federal prosecutors make another claim against Mallinckrodt over Acthar prices

  March 4, 2020

• New estimate puts cost to develop a new drug at $1B, adding to long-running debate

  March 3, 2020

• Sangamo sees vindication in Biogen gene-editing deal

  Feb. 28, 2020

• Takeda's small celiac disease bet turns into acquisition

  Feb. 26, 2020

• Mallinckrodt offers $1.6B in deal to settle opioid claims

  Feb. 25, 2020

• In a nod toward pharma, ICER makes deal to access real-world evidence

  Feb. 24, 2020

• Coronavirus weighs on AstraZeneca's China expansion

  Feb. 14, 2020

• Merck builds case for Keytruda use in breast cancer

  Feb. 12, 2020

• Exelixis prostate cancer data could help stave off competitive threats

  Feb. 11, 2020

• In Alzheimer's, a plan to treat patients earlier doesn't work out for Lilly, Roche

  Feb. 10, 2020

• Nestlé boosts investment as Aimmune preps launch of peanut allergy drug

  Feb. 5, 2020

• January price increases confirm slowing drug inflation

  Feb. 4, 2020

• US cancels trial after finding vaccine doesn't prevent HIV

  Feb. 3, 2020

• FDA approves Aimmune drug as first treatment for peanut allergy

  Jan. 31, 2020

• Amgen, Pfizer biosimilar sales pressure top drugs

  Jan. 31, 2020

• Preventive Alzheimer's trial data due within weeks, Lilly says

  Jan. 30, 2020

• Decibel CEO steps down as company pares workforce

  Jan. 29, 2020

• Pfizer lays out gene therapy aspirations

  Jan. 28, 2020

• To close merger, AbbVie and Allergan sell digestive drug to AstraZeneca

  Jan. 27, 2020

• FDA decision nears on Aimmune's contested peanut allergy drug

  Jan. 24, 2020

• Roche strengthens case for SMA drug with new study data

  Jan. 23, 2020

• Safety risks highlighted in FDA letter on Sarepta's Vyondys

  Jan. 22, 2020

• BeiGene cancer drug data sets up China duel with Merck

  Jan. 21, 2020

• Lilly seeking out more 'Dermira-like' deals: report

  Jan. 17, 2020

• Civica advances drug supply strategy with Thermo Fisher deal

  Jan. 16, 2020

• Astellas swoops in for Adaptimmune deal a day after positive data

  Jan. 14, 2020

• Biogen finds $75M home for Pfizer Alzheimer's drug

  Jan. 13, 2020

• Ultragenyx boosted by trial data for 2nd gene therapy

  Jan. 10, 2020

• 5 trends to watch at the FDA in 2020

  Jan. 9, 2020

• Solid cuts one-third of staff, goes all in on delayed gene therapy

  Jan. 9, 2020

• AbbVie to house Allergan Botox business in separate unit

  Jan. 8, 2020

• Merck's Keytruda falls short of rivals in 1 lung cancer type

  Jan. 7, 2020

• Merck adds to lung cancer wall with Otsuka deal

  Jan. 6, 2020

• Wave's Huntington's drug shows effect but falls short of mark set by Roche and Ionis

  Jan. 2, 2020

• AstraZeneca and Merck's Lynparza cleared by FDA for pancreatic cancer

  Dec. 30, 2019

• Roche hands $1B to Sarepta in major return to gene therapy deals

  Dec. 23, 2019

• Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals

  Dec. 20, 2019

• AstraZeneca lupus drug shows potential, but it may not be enough for FDA

  Dec. 19, 2019

• Muscle data doesn't help Solid build faith in its gene therapy

  Dec. 18, 2019

• BeiGene's Brukinsa bet falls short against Imbruvica

  Dec. 16, 2019

• Wave cancels its Exondys competitor and heads back to the lab in muscular dystrophy

  Dec. 16, 2019

• In stunning twist, FDA approves Sarepta's Duchenne drug it rejected

  Dec. 12, 2019

• House passes drug pricing bill that pharma warned would bring 'nuclear winter'

  Dec. 12, 2019

• Value-based pricing for gene therapy? Maybe not ready for hemophilia

  Dec. 11, 2019

• UniQure, Pfizer updates hint at gene therapy potential in hemophilia B

  Dec. 10, 2019

• Leukemia rivals try to stay ahead as Merck, Lilly chase

  Dec. 10, 2019

• As CAR-T presses ahead in multiple myeloma, alternative approaches gain supporters

  Dec. 9, 2019

• Pharma of the Year: AstraZeneca

  Dec. 9, 2019

• Disruptor of the Year: The Federal Trade Commission

  Dec. 9, 2019

• We're not for sale, Alexion executives declare

  Dec. 6, 2019

• Cancer gene therapy backed by Blackstone gets trial win

  Dec. 5, 2019

• New approval for Roche's Tecentriq heats up lung cancer battle with Keytruda

  Dec. 4, 2019

• Will sky-high drug prices spur the US to use an obscure power over patents?

  Dec. 4, 2019

• Opioid makers subject of US grand jury probe

  Nov. 27, 2019

• Global Blood's sickle cell drug wins FDA approval, joining Novartis' Adakveo

  Nov. 25, 2019

• What Novartis needs to do to make Medicines Co. deal a success

  Nov. 25, 2019

• Calquence OK boosts AstraZeneca's challenge to Imbruvica

  Nov. 22, 2019

• FDA's rapid review pace nets an early approval for Alnylam's second drug

  Nov. 20, 2019

• France clears way for wide use of Vertex's Orkambi

  Nov. 20, 2019

• Alkermes follows up restructuring with Rodin acqusition

  Nov. 18, 2019

• Novartis sickle cell drug wins FDA approval

  Nov. 15, 2019

• BeiGene FDA cancer drug nod seen as breakthrough for Chinese biopharma

  Nov. 15, 2019

• Sarepta brings in more gene therapies with StrideBio deal

  Nov. 14, 2019

• ICER draws new gene therapy pricing framework

  Nov. 13, 2019

• Solid gene therapy trial halted again by FDA

  Nov. 12, 2019

• Roche's oral SMA drug scores in older patients

  Nov. 11, 2019

• Fibrogen, AstraZeneca confirm roxadustat's heart safety months after confusing first readout

  Nov. 8, 2019

• Sarepta tries softer approach to resolve FDA setback

  Nov. 8, 2019

• Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout

  Nov. 7, 2019

• AstraZeneca's China ambitions grow with new R&D investments

  Nov. 6, 2019

• Third Neulasta biosimilar on its way as Sandoz wins long-delayed FDA approval

  Nov. 5, 2019

• Halozyme laying off 160 after pancreatic cancer trial comes up short

  Nov. 4, 2019

• Amgen's China ambitions become clear with BeiGene deal

  Nov. 1, 2019

• Sanofi pays $315 million to settle Lemtrada go-slow claims

  Oct. 31, 2019

• Novartis gene therapy ambitions dealt another blow by FDA hold on Zolgensma

  Oct. 30, 2019

• AstraZeneca joins Bristol-Myers' run at Merck in lung cancer

  Oct. 28, 2019

• Allergan pays $750M to rid itself of Namenda antitrust charges

  Oct. 28, 2019

• AstraZeneca blood cancer drug heading for showdown with AbbVie's

  Oct. 24, 2019

• Longtime Lilly diabetes chief Conterno to step down

  Oct. 23, 2019

• 7 questions on Biogen's revival of a failed Alzheimer's drug

  Oct. 22, 2019

• Teva offers $23B of Suboxone to get out of opioid litigation

  Oct. 21, 2019

• Drug distributors, Teva settle in Ohio opioid case

  Oct. 21, 2019

• Merck's Ebola vaccine wins key European vote

  Oct. 18, 2019

• Give up board chairmanship? No thanks, US big pharma CEOs say

  Oct. 16, 2019

• Lilly shuttering UK neuroscience research site

  Oct. 15, 2019

• Pelosi drug plan would save $370B, but could reduce R&D, forecasters say

  Oct. 14, 2019

• On second thought, AbbVie's new arthritis drug not so costly, ICER says

  Oct. 11, 2019

• ProQR eye-disease data lend confidence that pivotal trial will succeed

  Oct. 10, 2019

• Feeling pressure in hemophilia, Novo signs gene editing deal with Bluebird

  Oct. 9, 2019

• Akcea inks deal with Pfizer, rebounding after leadership shuffle

  Oct. 7, 2019

• Sarepta, in shadow of FDA setback, marks gene therapy progress

  Oct. 4, 2019

• Amicus rare disease data build hope for approval

  Oct. 2, 2019

• FDA knocks back AstraZeneca's respiratory ambitions

  Oct. 1, 2019

• AstraZeneca, Merck strengthen lead in PARP drug class

  Sept. 28, 2019

• Medicines Co. gets cholesterol confirmation

  Sept. 25, 2019

• Clovis shares plunge after downgrade raises questions on path forward

  Sept. 24, 2019

• Amag fights activist investor's bid for board seats

  Sept. 23, 2019

• Is the future of diabetes treatment better drugs or better care?

  Sept. 23, 2019

• Novo gains approval for first oral diabetes drug of its kind

  Sept. 20, 2019

• The top drugs facing cuts under Pelosi's pricing plan

  Sept. 20, 2019

• House Democrats forge ahead with direct Medicare drug price negotiation

  Sept. 19, 2019

• Acceleron dealt pipeline setback

  Sept. 17, 2019

• 5 questions ESMO cancer drug data might answer

  Sept. 16, 2019

• Another BACE dropped as Biogen and Eisai halt elenbecestat trials

  Sept. 13, 2019

• Adverum sinks on first gene therapy data for eye disease

  Sept. 12, 2019

• ICER dings Novo's new oral diabetes drug

  Sept. 11, 2019

• Medicare would negotiate prices for 250 drugs under House Democrats' plan

  Sept. 10, 2019

• Trial win could drive Acadia's Nuplazid to new use

  Sept. 9, 2019

• Roivant offloads biotech stakes in $3B alliance with Japanese pharma

  Sept. 6, 2019

• Novo Nordisk Foundation makes green grant to Danish-US university collaboration

  Sept. 5, 2019

• Ultragenyx gene therapy data disappoints investors

  Sept. 5, 2019

• Medicines Co.'s cholesterol drug looks good to take on PCSK9 rivals

  Sept. 2, 2019

• Novartis vies for multiple sclerosis dominance with Arzerra trial

  Aug. 30, 2019

• AstraZeneca gets lupus win but past failure could slow progress

  Aug. 29, 2019

• Amyloid's last hope? Prevention studies next big test for Alzheimer's research

  Aug. 29, 2019

• Immatics shows Celgene isn't done stocking cell therapy pipeline

  Aug. 28, 2019

• Gene editing companies oppose altering of embryos

  Aug. 27, 2019

• To patients, Sarepta repeats message on surprise rejection of Duchenne drug

  Aug. 22, 2019

• Sarepta now needs flawless progress for gene therapy

  Aug. 20, 2019

• Sarepta Duchenne drug rejected by FDA in surprise setback

  Aug. 19, 2019

• Pharming deal shows there's still life in struggling cancer drug class

  Aug. 15, 2019

• Regeneron gets cholesterol drug win where Praluent won't go

  Aug. 14, 2019

• Deciphera success sets up 2-horse race in gastrointestinal cancer

  Aug. 13, 2019

• AstraZeneca cancer drugs build as primary care shrinks

  Aug. 12, 2019

• Nektar battered over manufacturing issues and Bristol-Myers pullback

  Aug. 9, 2019

• Hospitalized gene therapy patient triggers Sarepta sell off

  Aug. 8, 2019

• Lilly shuffles executives overseeing oncology and M&A

  Aug. 7, 2019

• Teva finance chief resigns in midst of restructuring

  Aug. 7, 2019

• Amneal founders take reins as business struggles mount

  Aug. 5, 2019

• Sickle-cell setback triggers share slide at GlycoMimetics

  Aug. 5, 2019

• Takeda board lays out Shire integration goals

  Aug. 2, 2019

• Medicines Co. awaits its date with destiny

  Aug. 1, 2019

• White House backs importing drugs from abroad

  July 31, 2019

• How Mylan ended as a junior partner in its Pfizer deal

  July 30, 2019

• Mylan's tumble ends with Pfizer rescue

  July 29, 2019

• Senate advances drug pricing bill, setting up September vote

  July 26, 2019

• Roche highlights growth ahead of US biosimilar storm

  July 25, 2019

• Senate committee targets drug price increases with broad bill

  July 23, 2019

• Nonprofit US generics company secures supplier in Hikma

  July 23, 2019

• Opioid and price fixing legal liabilities mount for generic companies

  July 22, 2019

• Ultragenyx close to learning whether gene therapy gamble will pay off

  July 19, 2019

• MyoKardia cuts all ties to Sanofi

  July 18, 2019

• Merck urges caution on use of its newly approved antibacterial

  July 17, 2019

• Advocacy group pledges six-figure ad buy to support Trump drug price plan

  July 17, 2019

• Xarelto falls into the donut hole

  July 16, 2019

• AbbVie bets on early immuno-oncology asset

  July 15, 2019

• Amgen and Novartis halt Alzheimer's studies as faith in amyloid hypothesis dims

  July 12, 2019

• Billion-dollar settlement gets Reckitt out of federal opioid probes

  July 11, 2019

• In win for pharma, Trump TV drug price rule struck down

  July 9, 2019

• Roche acknowledges the obvious, extends Spark buyout deadline

  July 8, 2019

• Array pushed Pfizer for a higher price to get deal done

  July 1, 2019

• Pfizer muscular dystrophy gene therapy stumbles on safety

  June 28, 2019

• Zogenix boosted on FDA about-face for seizure drug application

  June 27, 2019

• AstraZeneca gets immuno-oncology win in a disease that Merck doesn't rule

  June 27, 2019

• AbbVie deal for Allergan not about the taxes, thanks to 2017 law

  June 26, 2019

• Novartis fights off generics courtroom challenge

  June 25, 2019

• Bristol-Myers price for Celgene now includes Otezla sell-off

  June 24, 2019

• Beating Keytruda a big task, Exelixis and Roche find

  June 21, 2019

• Sanofi to cut 466 workers in Europe as it seeks to refocus R&D

  June 20, 2019

• Pfizer goes big on targeted cancer therapies with $11.4B Array buy

  June 17, 2019

• Bluebird sets $1.8M price tag for blood-disease gene therapy

  June 14, 2019

• Upadacitinib a plus for AbbVie in rheumatoid arthritis, doc survey says

  June 14, 2019

• Savara lung disease trial misses, but execs vow to press on

  June 13, 2019

• FTC demands could mean months-long delay for Roche-Spark deal

  June 12, 2019

• Novo Nordisk goes for broke on semaglutide heart data

  June 11, 2019

• Trulicity heart data falls short for Lilly investors

  June 10, 2019

• Amicus widens UPenn gene therapy collaboration

  May 29, 2019

• BioMarin readies hemophilia gene therapy for FDA submission

  May 28, 2019

• Pay-for-delay deals disappearing, FTC says

  May 24, 2019

• Could Novartis' gene therapy have more than one price?

  May 23, 2019

• 5 novel immuno-oncology targets to know before ASCO

  May 22, 2019

• No news is bad news for Tocagen

  May 22, 2019

• Array gets a win in colorectal cancer

  May 21, 2019

• Long-term heart data reassures for Medicines Co.

  May 20, 2019

• Medicare decides against tighter management of HIV drugs

  May 17, 2019

• Breast cancer survival data buoys Macrogenics and Puma

  May 16, 2019

• Cost-effectiveness agency clears Biogen's Spinraza for UK patients

  May 15, 2019

• Solid's gene therapy stumble makes Sarepta's lead clearer

  May 14, 2019

• Generics price-fixing lawsuit focuses on Teva's role as catalyst

  May 13, 2019

• Fibrogen confuses as it tries to explain blood-boosting drug data

  May 10, 2019

• Biopharma happily takes the tax cuts, but the jobs are harder to find

  May 9, 2019

• AstraZeneca's share dilution gamble on Daiichi drug pays off

  May 8, 2019

• Roche risdiplam data heats up SMA rivalry with Novartis

  May 7, 2019

• Novartis makes final Zolgensma pitch before FDA decision

  May 6, 2019

• Approval of $225,000-a-year tafamidis comes early for Pfizer

  May 6, 2019

• Rebate ban not a magic balm, federal budget forecasters say

  May 3, 2019

• Cost cuts to the rescue for Teva, so far

  May 2, 2019

• Generic Advair hits GSK revenues hard

  May 1, 2019

• Pfizer prospects for tafamidis market

  April 30, 2019

• Alexion, AstraZeneca secure backing of EMA panel for key drugs

  April 29, 2019

• Roche's takeout of Spark not working like a Swiss watch

  April 26, 2019

• Don't worry about Humira biosimilars, the pipeline will deliver, AbbVie says

  April 25, 2019

• Medicare proposes raising CAR-T pay, but reimbursement solution years away

  April 24, 2019

• Competition and donut hole discount takes toll on Xarelto sales

  April 23, 2019

• Safety setback for Pfizer, Lilly pain drug should have Regeneron and Teva feeling nervous

  April 22, 2019

• $300M loan boosts launch of TherapeuticsMD hot flash pill

  April 18, 2019

• Sarepta may have seen off another rival in Wave

  April 17, 2019

• Its ambitions restrained, Amgen sets modest Evenity price

  April 16, 2019

• Kidney data may give J&J diabetes drug an edge

  April 15, 2019

• Gilead and Novo Nordisk pair up to take on NASH

  April 12, 2019

• Intercept sputters as it reveals full Ocaliva NASH data to doctors

  April 11, 2019

• Indivior draws criminal indictment for opioid marketing practices

  April 10, 2019

• Pharmacy's 'middlemen' counter pharma's campaign to shift the price blame

  April 9, 2019

• Audentes lays down marker in muscular dystrophy

  April 8, 2019

• Copay assistance snares 3 drug companies in Medicare kickback charges

  April 5, 2019

• What to look for after Zolgensma's launch

  April 4, 2019

• Roche must ask Spark shareholders once again to sell

  April 3, 2019